[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 168
1. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res; 2010 Nov 1;70(21):8309-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of recurrent breast cancer using metabolite profiling.
  • We report on the development of a monitoring test for recurrent breast cancer, using metabolite-profiling methods.
  • Using a combination of nuclear magnetic resonance (NMR) and two-dimensional gas chromatography-mass spectrometry (GC×GC-MS) methods, we analyzed the metabolite profiles of 257 retrospective serial serum samples from 56 previously diagnosed and surgically treated breast cancer patients.
  • One hundred sixteen of the serial samples were from 20 patients with recurrent breast cancer, and 141 samples were from 36 patients with no clinical evidence of the disease during ∼6 years of sample collection.
  • Strikingly, 55% of the patients could be correctly predicted to have recurrence 13 months (on average) before the recurrence was clinically diagnosed, representing a large improvement over the current breast cancer-monitoring assay CA 27.29.
  • To the best of our knowledge, this is the first study to develop and prevalidate a prediction model for early detection of recurrent breast cancer based on metabolic profiles.
  • In particular, the combination of two advanced analytical methods, NMR and MS, provides a powerful approach for the early detection of recurrent breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] NMR Biomed. 2002 Aug;15(5):327-37 [12203224.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1217-22 [11953875.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1875-82 [6090002.001]
  • [Cites] Cancer. 1992 May 1;69(9):2343-8 [1562982.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):420-7 [7812974.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2322-8 [9196146.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3791-9 [9731486.001]
  • [Cites] J Magn Reson. 1998 Nov;135(1):194-202 [9799694.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1191-7 [9848727.001]
  • [Cites] Clin Chem. 1999 May;45(5):630-7 [10222349.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):782-8 [15499633.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):267-76 [15894488.001]
  • [Cites] NMR Biomed. 2006 Feb;19(1):30-40 [16229059.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):345-51 [16410341.001]
  • [Cites] Nature. 2006 Apr 20;440(7087):1073-7 [16625200.001]
  • [Cites] BMC Cancer. 2006;6:220 [16953875.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6 [17202168.001]
  • [Cites] Anal Bioanal Chem. 2007 Jan;387(2):525-7 [16955259.001]
  • [Cites] Breast Cancer Res Treat. 2007 Aug;104(2):181-9 [17061040.001]
  • [Cites] Pac Symp Biocomput. 2007;:157-68 [17990489.001]
  • [Cites] Pac Symp Biocomput. 2007;:181-92 [17990491.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5287-312 [17954709.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83 [18695137.001]
  • [Cites] Cell. 2008 Sep 5;134(5):714-7 [18775301.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Sep;8(5):617-33 [18785810.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Breast Cancer Res Treat. 2009 Apr;114(3):403-12 [18421576.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1505-10 [19297316.001]
  • [Cites] J Proteome Res. 2010 Feb 5;9(2):972-9 [19994911.001]
  • [Cites] Cancer Biol Ther. 2010 Feb;9(4):266-73 [20026902.001]
  • [Cites] Xenobiotica. 1999 Nov;29(11):1181-9 [10598751.001]
  • [Cites] Oncology. 2000 Apr;58(3):185-90 [10765118.001]
  • [Cites] Cancer Treat Rev. 2000 Apr;26(2):91-102 [10772967.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):688-95 [11830521.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4105-8 [11911301.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3195-201 [12810648.001]
  • (PMID = 20959483.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM085291; United States / NCI NIH HHS / CA / R25 CA128770; United States / NIGMS NIH HHS / GM / R01GM085291-02; United States / NCI NIH HHS / CA / R25CA128770
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS232187; NLM/ PMC2995269
  •  go-up   go-down


2. Villa LL: Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine; 2006 Mar 30;24 Suppl 1:S23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HPV-associated diseases, such as cervical and other anogenital cancers, cervical and anal intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis confer considerable morbidity and mortality, and are significant health care concerns.
  • To derive the greatest public health benefit, HPV vaccines offering protection from cervical cancer and genital warts will, ideally, be administered prior to the initiation of sexual activity; therefore, educational initiatives will be essential to communicate the risks and adverse consequences of HPV infection and to foster widespread vaccine acceptance.


3. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • The aim of this study was to examine our experience with abdominoperineal resection (APR) in cases of persistent or recurrent SCCA with an emphasis on survival and morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


Advertisement
4. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R: Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res; 2009 Dec 15;15(24):7693-7700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
  • PURPOSE: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy.
  • EXPERIMENTAL DESIGN: RNA was extracted from archived tumor samples derived from 378 patients with stage I to III HR-positive, HER2-normal breast cancer and analyzed by reverse transcription-PCR for a panel of 374 genes, including the 21-gene recurrence score (RS).
  • All available recurrent cases were selected plus a nonrecurrent cohort.
  • CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker. (Clin Cancer Res 2009;15(24):7693-700).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996222.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / U10 CA014958-28; United States / NCI NIH HHS / CA / U10 CA014958-32; United States / NCI NIH HHS / CA / U10 CA014958-29; United States / NCI NIH HHS / CA / U10 CA014958-31; United States / NCI NIH HHS / CA / U10 CA014958; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA014958-33; United States / NCI NIH HHS / CA / U10 CA014958-30; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / U10 CA014958-34; United States / NCI NIH HHS / CA / U10 CA014958-35; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Prudhomme M, Dehni N, Dozois RR, Tiret E, Parc R: Causes and outcomes of pouch excision after restorative proctocolectomy. Br J Surg; 2006 Jan;93(1):82-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pouch failure occurs in up to 10 per cent of patients after ileal pouch-anal anastomosis (IPAA).
  • Fourteen patients with Crohn's disease developed extensive fistulous disease and/or recurrent abscesses, of whom six had a persistent perineal sinus after pouch excision.
  • Three patients had chronic ulcerative colitis and developed recurrent pelvic sepsis.
  • Finally, two patients with multiple colorectal adenocarcinoma developed recurrent cancer (one) or sepsis (one).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16288450.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Kumánovics A, Wittwer CT, Pryor RJ, Augustine NH, Leppert MF, Carey JC, Ochs HD, Wedgwood RJ, Faville RJ Jr, Quie PG, Hill HR: Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases. J Mol Diagn; 2010 Mar;12(2):213-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases.

  • Genetic Alliance. consumer health - Hyperimmunoglobulin E recurrent infection syndrome, autosomal dominant.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 2006 Apr;117(4):725-38; quiz 739 [16630926.001]
  • [Cites] Immunol Rev. 2005 Feb;203:244-50 [15661034.001]
  • [Cites] Nat Protoc. 2007;2(1):59-66 [17401339.001]
  • [Cites] J Allergy Clin Immunol. 2007 May;119(5):1234-40 [17335882.001]
  • [Cites] Immunity. 2007 May;26(5):535; author reply 536 [17521577.001]
  • [Cites] Pharmacogenomics. 2007 Jun;8(6):597-608 [17559349.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1058-62 [17676033.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1608-19 [17881745.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):773-6 [18337720.001]
  • [Cites] Immunol Allergy Clin North Am. 2008 May;28(2):277-91, viii [18424333.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jul;122(1):181-7 [18602572.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1551-7 [18591410.001]
  • [Cites] Mol Immunol. 2008 Nov;46(1):202-6 [18706697.001]
  • [Cites] Hum Mutat. 2009 Jun;30(6):899-909 [19370767.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):853-60 [12765979.001]
  • [Cites] J Pediatr. 2004 Jan;144(1):93-9 [14722525.001]
  • [Cites] Lancet. 1966 May 7;1(7445):1013-5 [4161105.001]
  • [Cites] Pediatrics. 1972 Jan;49(1):59-70 [5059313.001]
  • [Cites] Ann Intern Med. 1975 Jun;82(6):766-71 [1138587.001]
  • [Cites] Cancer. 1977 Jun;39(6):2386-90 [326374.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] J Pediatr. 1998 Aug;133(2):303-5 [9709729.001]
  • [Cites] N Engl J Med. 1999 Mar 4;340(9):692-702 [10053178.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2521-5 [15621772.001]
  • [Cites] Immunity. 2006 Nov;25(5):745-55 [17088085.001]
  • (PMID = 20093388.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  • [Other-IDs] NLM/ PMC2871728
  •  go-up   go-down


7. Petrie N, Branagan G, McGuiness C, McGee S, Fuller C, Chave H: Reconstruction of the perineum following anorectal cancer excision. Int J Colorectal Dis; 2009 Jan;24(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction of the perineum following anorectal cancer excision.
  • PURPOSE: Most patients with anal cancer receive chemoradiotherapy as first-line treatment.
  • Persistent/recurrent tumours will subsequently require an abdomino-perineal resection (APR).
  • A proportion of the 20,000 new cases of rectal carcinoma diagnosed in the UK each year receive neo-adjuvant chemoradiation and then an APR.
  • This study investigates a series of 18 patients who underwent APR for anorectal cancer with flap reconstruction of their perineum.
  • RESULTS: Between November 2000 and October 2007, 18 cases were performed (M/F = 7:11), six for anal cancer and 12 for low rectal tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / therapy. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Length of Stay. Male. Middle Aged. Neoadjuvant Therapy. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Wound Healing

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2000 Jan;105(1):171-3 [10626987.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):886-91 [11485523.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Plast Reconstr Surg. 2001 Dec;108(7):1998-2005 [11743391.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] J Reconstr Microsurg. 1998 Jul;14(5):337-40 [9714040.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] Int J Colorectal Dis. 1991 Nov;6(4):193-6 [1770285.001]
  • [Cites] Wound Repair Regen. 1998 May-Jun;6(3):223-33 [9776866.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):232-8 [17143848.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1961 May;85:822-33 [13685884.001]
  • [Cites] Dis Colon Rectum. 1980 Nov-Dec;23(8):564-6 [7460694.001]
  • [Cites] Br J Plast Surg. 1996 Dec;49(8):547-54 [8976747.001]
  • [Cites] Ann R Coll Surg Engl. 1984 Sep;66(5):337-9 [6237602.001]
  • [Cites] Plast Reconstr Surg. 1988 Jan;81(1):62-73 [2962215.001]
  • [Cites] CA Cancer J Clin. 1971 Nov-Dec;21(6):361-4 [5001853.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Ann Intern Med. 1980 Sep;93(3):480-9 [6254418.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):349-54 [10201777.001]
  • [Cites] Surg Gynecol Obstet. 1981 Nov;153(5):713-6 [7292271.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Ann R Coll Surg Engl. 1995 May;77(3):229-32 [7598425.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] J Natl Cancer Inst. 1971 Oct;47(4):865-70 [5097154.001]
  • [Cites] Scand J Plast Reconstr Surg. 1975;9(1):74-6 [1162294.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1983 Jan;145(1):183-9 [6849490.001]
  • [Cites] Br J Surg. 1990 Jun;77(6):635-7 [2143427.001]
  • [Cites] Am J Surg. 1974 Feb;127(2):215-9 [4812123.001]
  • [Cites] Otolaryngology. 1978 Sep-Oct;86(5):ORL-804-11 [114952.001]
  • [Cites] Ann Plast Surg. 2004 Jan;52(1):22-6 [14676694.001]
  • [Cites] Cancer Res. 1958 Apr;18(3):305-17 [13523597.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):33-7 [10030413.001]
  • [Cites] Plast Reconstr Surg. 1988 Oct;82(4):669-77 [3420190.001]
  • [Cites] J Reconstr Microsurg. 1998 May;14(4):263-8 [9618094.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):777-83 [9240646.001]
  • [Cites] Can J Surg. 1987 May;30(3):212-4 [3580983.001]
  • [Cites] Oncologist. 2002;7(3):188-99 [12065790.001]
  • (PMID = 18688618.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Ramamoorthy S, Luo L, Luo E, Carethers JM: Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev; 2008;32(2):116-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and risk of recurrence for squamous cell cancer of the anus.
  • OBJECTIVE: Squamous cell cancer of the anus is associated with multiple risk factors, including infection with human papillomavirus, immunosuppression, chronic inflammation, and tobacco smoking, although there is little data on these factors for the prediction of recurrent disease.
  • Here, we evaluated the risk of recurrence and mortality of anal carcinoma in association with tobacco smoking.
  • METHODS: We conducted a retrospective review of cases of anal carcinoma from two local hospitals.
  • We obtained information on treatment response and cancer recurrence, as well as tobacco usage from medical records.
  • RESULTS: We identified 64 patients with squamous cell cancer of the anus, and 34 of these (53%) had a tobacco smoking history.
  • Current smokers had higher carcinoma recurrence rates (11/34, 32%) than non-smokers (6/30, 20%).
  • Overall mortality was 33% (21/64), and cancer-related mortality was 23% (15/64).
  • CONCLUSION: Tobacco smoking appears to be associated with anal carcinoma disease recurrence, and is related to increased mortality.
  • This data suggests that patients should be cautioned about tobacco smoking once a diagnosis of anal carcinoma is made in attempt to improve their long-term outcome.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Anesth Analg. 1986 Nov;65(11):1186-8 [3767017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Prev Med. 1995 Jul-Aug;11(4):245-50 [7495601.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):853-8 [16815535.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):808-12 [11017836.001]
  • (PMID = 18639388.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NIDDK NIH HHS / DK / DK067287-01A2; United States / NIDDK NIH HHS / DK / R24 DK080506-01; United States / NIDDK NIH HHS / DK / R01 DK067287-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS209533; NLM/ PMC3427794
  •  go-up   go-down


9. Sun Y: Estimation of semiparametric regression model with longitudinal data. Lifetime Data Anal; 2010 Apr;16(2):271-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The method is illustrated with a data set from a recurrent bladder cancer study.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lifetime Data Anal. 2002 Sep;8(3):247-62 [12182121.001]
  • [Cites] Biostatistics. 2005 Jul;6(3):374-94 [15831584.001]
  • [Cites] Biometrics. 1994 Sep;50(3):689-99 [7981395.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):297-312 [12925523.001]
  • (PMID = 19890712.001).
  • [ISSN] 1572-9249
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI054165; None / None / / R01 AI054165-04; United States / NIAID NIH HHS / AI / R37 AI054165; United States / NIAID NIH HHS / AI / R01 AI054165-04
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161826; NLM/ PMC3043558
  •  go-up   go-down


10. Haboubi NY, Edilbe MW, Hill J: Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline. Colorectal Dis; 2007 Mar;9(3):238-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline.
  • The currently accepted first line treatment for epidermoid anal cancer is chemoradiotherapy (CRT).
  • Residual or recurrent disease following initial CRT, is best treated by salvage anorectal excision.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298622.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Murrell ZA, Dixon MR, Vargas H, Arnell TD, Kumar R, Stamos MJ: Contemporary indications for and early outcomes of abdominoperineal resection. Am Surg; 2005 Oct;71(10):837-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for operation were primary rectal cancer (n = 31), recurrent rectal cancer (n = 6), intractable Crohn disease (n = 3), anal melanoma (n = 1), cloacogenic cancer (n = 1), squamous cell cancer (n = 1), and gastrointestinal stromal tumor (n = 1).
  • Despite the significant morbidity associated with this surgery, APR may provide beneficial treatment for select cases of low rectal cancer, end-stage inflammatory bowel disease, and anal malignancies.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468531.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Habr-Gama A: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. Tech Coloproctol; 2006 Dec;10(4):382; discussion 382
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219047.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Van Daele DJ: Quantitative PCR analysis of laryngeal muscle fiber types. J Commun Disord; 2010 Jul-Aug;43(4):327-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Voice and swallowing dysfunction as a result of recurrent laryngeal nerve paralysis can be improved with vocal fold injections or laryngeal framework surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20430402.001).
  • [ISSN] 1873-7994
  • [Journal-full-title] Journal of communication disorders
  • [ISO-abbreviation] J Commun Disord
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / R13 DC003383
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger; EC 3.6.4.1 / Myosin Heavy Chains
  • [Other-IDs] NLM/ NIHMS455793; NLM/ PMC4530018
  •  go-up   go-down


14. Patel CB, Ramos-Valadez DI, Haas EM: Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations. Int J Med Robot; 2010 Dec;6(4):399-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations.
  • BACKGROUND: Robotic-assisted laparoscopic surgery is an emerging technology that may prove advantageous for complex colorectal procedures involving the irradiated pelvis, such as abdominoperineal resection for recurrent anal cancer.
  • METHODS: Over a 6 month period, five abdominoperineal resections were performed using the da Vinci® robot for recurrent anal cancer in patients initially treated with definitive chemoradiation therapy.
  • CONCLUSION: Robotic-assisted laparoscopic surgery for anal cancer was found to be a safe and feasible procedure.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Laparoscopy / methods. Perineum / surgery. Robotics / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20827795.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Dunn JM, Mackenzie GD, Oukrif D, Mosse CA, Banks MR, Thorpe S, Sasieni P, Bown SG, Novelli MR, Rabinovitch PS, Lovat LB: Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer; 2010 May 25;102(11):1608-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: DNA ploidy abnormalities (aneuploidy/tetraploidy) measured by flow cytometry (FC) are strong predictors of future cancer development in untreated Barrett's oesophagus, independent of histology grade.
  • In the cohort study, there were 13 cases of late relapse (7 cancer, 6 HGD) and 17 patients who remained free of dysplasia after a mean follow-up of 44 months.
  • Aneuploidy post-PDT was highly predictive for recurrent HGD or cancer with a hazard ratio of 8.2 (1.8-37.8) (log-rank P=0.001).
  • After histologically successful PDT, patients with residual aneuploidy are significantly more likely to develop HGD or cancer than those who become diploid.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3413-9 [10606296.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Anal Cell Pathol. 1995 Jan;8(1):67-74 [7734413.001]
  • [Cites] Lasers Med Sci. 2008 Apr;23(2):203-10 [17610005.001]
  • [Cites] J Histochem Cytochem. 1983 Nov;31(11):1333-5 [6619538.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Crit Rev Clin Lab Sci. 1994;31(1):1-34 [8049032.001]
  • [Cites] Cytometry. 1994 Dec 15;18(4):218-22 [7895528.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Cytometry. 1992;13(6):577-85 [1451590.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3089-96 [11095322.001]
  • [Cites] Cytometry. 1992;13(3):314-21 [1576895.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Cytometry. 1995 Sep 15;22(3):181-9 [8556949.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Br J Obstet Gynaecol. 1994 Jul;101(7):621-5 [8043542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Lasers Med Sci. 2009 Sep;24(5):729-34 [19057983.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1595-607 [8156486.001]
  • [Cites] BMC Clin Pathol. 2008 May 30;8:5 [18513411.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):178-82 [2047381.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):470-6 [18553366.001]
  • [Cites] Methods Cell Biol. 1994;41:263-96 [7861967.001]
  • (PMID = 20461081.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A9022
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2883155
  •  go-up   go-down


16. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD: Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res; 2008 Dec 1;68(23):9663-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.
  • Radiation therapy is a first-line treatment for prostate cancer patients with localized tumors.
  • Although some patients respond well to the treatment, approximately 10% of low-risk and up to 60% of high-risk prostate cancer patients experience recurrent tumors.
  • Here we show that fractionated ionizing radiation (IR) induces differentiation of LNCaP prostate cancer cells into neuroendocrine (NE)-like cells, which are known to be implicated in prostate cancer progression, androgen-independent growth, and poor prognosis.
  • These results suggest that radiation therapy-induced NE-like differentiation may represent a novel pathway by which prostate cancer cells survive the treatment and contribute to tumor recurrence.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1987 Jul 9-15;328(6126):175-8 [2885756.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7156-68 [15466214.001]
  • [Cites] EMBO J. 1989 Jul;8(7):2023-8 [2529117.001]
  • [Cites] Genes Dev. 1989 Dec;3(12B):2083-90 [2516827.001]
  • [Cites] Oncogene. 1991 Nov;6(11):2019-26 [1658708.001]
  • [Cites] Curr Opin Genet Dev. 1992 Apr;2(2):199-204 [1386267.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):1967-70 [8481896.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):1184-96 [9492053.001]
  • [Cites] Urology. 1998 Apr;51(4):585-9 [9586611.001]
  • [Cites] Exp Cell Res. 1998 Aug 1;242(2):540-7 [9683540.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3821-30 [10447001.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2004;14(4):287-300 [15663358.001]
  • [Cites] J Mol Endocrinol. 2005 Feb;34(1):107-18 [15691881.001]
  • [Cites] Anal Chem. 2005 Mar 1;77(5):1295-302 [15732910.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jul;131(7):407-19 [15887028.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5263-71 [15958572.001]
  • [Cites] J Pathol. 2006 Feb;208(3):401-7 [16369914.001]
  • [Cites] EMBO J. 2006 Mar 8;25(5):1058-69 [16511568.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):151-67 [16601285.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10188-95 [16452470.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 May;26(5):1036-42 [16497991.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):523-33 [16820098.001]
  • [Cites] Front Biosci. 2007;12:1814-32 [17127423.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(1):6-14 [17075603.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1405-16 [17685384.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):531-47 [17914087.001]
  • [Cites] BJU Int. 2008 Mar;101 Suppl 2:11-5 [18307687.001]
  • [Cites] Biochim Biophys Acta. 2007 Feb;1769(2):79-91 [17337306.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3663-72 [17440078.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Jun;29(3):128-38 [17672372.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1008-20 [10629058.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):186-95 [10639189.001]
  • [Cites] Annu Rev Biochem. 1999;68:821-61 [10872467.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609 [11483993.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S135-40 [11762341.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S141-4 [11762342.001]
  • [Cites] Cell. 2002 Mar 8;108(5):689-703 [11893339.001]
  • [Cites] Prostate. 2002 May 1;51(2):117-25 [11948966.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] J Neurobiol. 2003 Apr;55(1):14-24 [12605455.001]
  • [Cites] Exp Cell Res. 2003 Aug 1;288(1):198-207 [12878171.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1726-37 [12775765.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6704-16 [14555984.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] J Cell Physiol. 2004 Mar;198(3):428-40 [14755548.001]
  • [Cites] Cell Death Differ. 2004 Mar;11(3):321-30 [14685164.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5489-95 [15289359.001]
  • [Cites] J Neurosci. 1988 Apr;8(4):1425-35 [3282037.001]
  • (PMID = 19047143.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023168-26S1; United States / NCI NIH HHS / CA / CA023168-28S1; United States / NCI NIH HHS / CA / P30 CA023168-28; United States / NCI NIH HHS / CA / P30 CA023168-26; United States / NCI NIH HHS / CA / CA023168-27S1; United States / NCI NIH HHS / CA / CA023168-27; United States / NCI NIH HHS / CA / P30 CA023168-28S1; United States / NCI NIH HHS / CA / P30 CA023168-27S1; United States / NCI NIH HHS / CA / P30 CA023168-27; United States / NCI NIH HHS / CA / P30 CA023168-25; United States / NCI NIH HHS / CA / P30 CA023168-24; United States / NCI NIH HHS / CA / CCSG CA23168; United States / NCI NIH HHS / CA / P30 CA023168
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATF2 protein, human; 0 / Activating Transcription Factor 2; 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein
  • [Other-IDs] NLM/ NIHMS289051; NLM/ PMC3100895
  •  go-up   go-down


17. Lin TY, Thomas R, Tsai PC, Breen M, London CA: Generation and characterization of novel canine malignant mast cell line CL1. Vet Immunol Immunopathol; 2009 Jan 15;127(1-2):114-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lastly, cytogenetic evaluation revealed several recurrent tumor-associated chromosome copy number imbalances in the CL1 line.


18. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


19. Weyandt GH: [Acute and chronic anal ulcers]. Hautarzt; 2010 Jan;61(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute and chronic anal ulcers].
  • Classic types of anal ulcers are acute and chronic anal fissure.
  • Characteristic symptoms of chronic fissures are severe pain during defecation accompanied by the triad of ulceration, hypertrophic anal papilla and external skin tag.
  • The special setting in the anal fold, especially with concurrent immunosuppression, could lead to nonspecific manifestations of different proctological, dermatological and infectious diseases, which can only be clarified by further diagnostic workup and histopathology.
  • Successfully treated inflammatory dermatoses and precancerous lesions require regular follow-up because a recurrent or persistent course of the disease may result in malignant transformation.
  • [MeSH-major] Fissure in Ano / diagnosis. Fissure in Ano / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dtsch Dermatol Ges. 2003 Nov;1(11):864-8 [16281576.001]
  • [Cites] Hautarzt. 2004 Mar;55(3):259-64 [15029432.001]
  • [Cites] Hautarzt. 1997 Mar;48(3):199-202 [9182093.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] MMWR Recomm Rep. 2006 Aug 4;55(RR-11):1-94 [16888612.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Oct;6(10):865-7 [18498379.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2341-8 [14556926.001]
  • [Cites] Hautarzt. 1972 May;23(5):228-9 [4557839.001]
  • [Cites] Int J Clin Pharmacol Ther Toxicol. 1993 Apr;31(4):204-7 [8388868.001]
  • [Cites] HNO. 2008 Mar;56(3):306-11 [17464493.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2001 Mar;15(2):126-36 [11495519.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Hautarzt. 2007 Mar;58(3):241-2, 244-5 [16874531.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 19997893.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS: Evaluating the impact of human papillomavirus vaccines. Vaccine; 2009 Jul 9;27(32):4355-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal).


21. Heyn J, Placzek M, Ozimek A, Baumgaertner AK, Siebeck M, Volkenandt M: Malignant melanoma of the anal region. Clin Exp Dermatol; 2007 Sep;32(5):603-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal region.
  • Malignant melanoma (MM) of the anal region is an uncommon disease.
  • Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.
  • We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.
  • [MeSH-major] Anus Neoplasms. Melanoma
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376215.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 25
  •  go-up   go-down


22. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Adjunct therapies have been utilized in more advanced or recurrent lesions, including radiotherapy, photodynamic therapy, and imiquimod.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


23. Zaragoza K, Bégay V, Schuetz A, Heinemann U, Leutz A: Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes. Mol Cell Biol; 2010 May;30(9):2293-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The myeloproliferative C/EBPalpha BRM2 mutant serves as a paradigm for recurrent human C-terminal bZIP C/EBPalpha mutations that are involved in acute myeloid leukemogenesis.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Aug 15;102(4):1267-75 [12702500.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):390-400 [19878871.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 21;318(1):213-8 [15110775.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):394-400 [15122210.001]
  • [Cites] Nature. 2004 Jun 17;429(6993):771-6 [15175761.001]
  • [Cites] Trends Biochem Sci. 2004 Aug;29(8):409-17 [15362224.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9744-51 [15509779.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):131-7 [2757186.001]
  • [Cites] EMBO J. 1992 Jan;11(1):115-26 [1346759.001]
  • [Cites] Genes Dev. 1992 Apr;6(4):533-44 [1373117.001]
  • [Cites] Genes Dev. 1993 Oct;7(10):1850-61 [8405995.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4317-24 [8223441.001]
  • [Cites] Science. 1993 Dec 3;262(5139):1557-60 [8248803.001]
  • [Cites] Cell. 1994 Jul 15;78(1):161-72 [8033208.001]
  • [Cites] Science. 1995 Aug 25;269(5227):1108-12 [7652557.001]
  • [Cites] Am J Physiol. 1995 Aug;269(2 Pt 1):L241-7 [7653587.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):24753-60 [8798745.001]
  • [Cites] Genes Dev. 1996 Nov 1;10(21):2794-804 [8946919.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74 [9012825.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21473-8 [9261165.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2014-22 [10688648.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5986-97 [10913181.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(19):7292-9 [10982846.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10826-31 [10995476.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):645-8 [11034215.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3037-50 [11114892.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3051-64 [11114893.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):135-47 [11237530.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):699-703 [11257102.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(11):3789-806 [11340171.001]
  • [Cites] Mol Carcinog. 2001 Jun;31(2):90-100 [11429786.001]
  • [Cites] Cell. 2001 Oct 19;107(2):247-58 [11672531.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):48-58 [11753385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):207-12 [11756662.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):245-56 [11799067.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Nucleic Acids Res. 2002 Mar 1;30(5):1240-6 [11861917.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2032-6 [11877276.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):39-49 [12110166.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):1443-9 [12446714.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1141-8 [12393450.001]
  • [Cites] Cell. 2003 May 16;113(4):495-506 [12757710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8858-63 [9671769.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7276-81 [10377405.001]
  • [Cites] N Engl J Med. 2004 Dec 2;351(23):2370-2 [15575052.001]
  • [Cites] J Cell Sci. 2005 Jun 15;118(Pt 12):2545-55 [15944395.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):85-96 [15983063.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15178-84 [12578822.001]
  • [Cites] EMBO J. 2005 Sep 21;24(18):3301-12 [16107878.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9678-86 [16266987.001]
  • [Cites] Development. 2006 Mar;133(6):1155-64 [16467360.001]
  • [Cites] Nucleic Acids Res. 2007;35(6):e43 [17311810.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6768-76 [17638888.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):299-310 [18394553.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(11):1516-23 [18515086.001]
  • [Cites] J Cell Biol. 2008 Oct 6;183(1):37-48 [18824566.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3163-71 [12869508.001]
  • (PMID = 20176812.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / E2F Transcription Factors; 0 / Mutant Proteins; 0 / Repressor Proteins; 0 / Retinoblastoma Protein; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2863587
  •  go-up   go-down


24. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1525-9 [9769399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Surg Gynecol Obstet. 1970 Nov;131(5):953-7 [5471546.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):997-1005 [11240240.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Plast Reconstr Surg. 1988 Jan;81(1):62-73 [2962215.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):105-10 [7834434.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Clin Plast Surg. 1990 Oct;17(4):705-12 [2249391.001]
  • [Cites] AJR Am J Roentgenol. 1979 Nov;133(5):790-5 [115262.001]
  • [Cites] Dis Colon Rectum. 1989 Sep;32(9):773-7 [2503342.001]
  • [Cites] Proc R Soc Med. 1941 Jan;34(3):139-60 [19992316.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1090-3; discussion 1094-5 [10982516.001]
  • [Cites] Surg Gynecol Obstet. 1985 Dec;161(6):509-17 [3934775.001]
  • [Cites] Br J Plast Surg. 1984 Jul;37(3):330-50 [6234962.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, Berkowitz RS: Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol; 2010 Dec;119(3):462-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
  • OBJECTIVE: CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels.
  • METHODS: CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded.
  • For nonmucinous invasive cancers, Jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher CA125, and greater body mass index (BMI), recurrent yeast infections, colitis, and appendectomy predicted lower CA125.
  • In multivariate modeling, stage, ascites, and prior breast cancer were the strongest predictors of high CA125 and appendectomy and yeast infections strongest predictors of low CA125.
  • CONCLUSIONS: Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer. 2000 Oct 1;89(7):1555-60 [11013371.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):934-8 [7547243.001]
  • [Cites] Obstet Gynecol. 2002 Jul;100(1):59-64 [12100804.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):438-42 [12366659.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):77-83 [12468346.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):150-4 [12620910.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Am J Med Sci. 1986 Jul;292(1):25-9 [3521278.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):202-7 [3471274.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):61-7 [2443433.001]
  • [Cites] Gynecol Obstet Invest. 1989;27(3):143-7 [2661359.001]
  • [Cites] Obstet Gynecol. 1990 Sep;76(3 Pt 1):428-31 [2381621.001]
  • [Cites] Obstet Gynecol. 1992 Jun;79(6):1002-10 [1579296.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):87-92 [1427408.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):42-7 [7789889.001]
  • [Cites] J Reprod Med. 1996 Mar;41(3):140-2 [8778409.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):305-13 [8975707.001]
  • [Cites] Acta Oncol. 1997;36(7):755-9 [9490096.001]
  • [Cites] Cancer. 1999 May 1;85(9):2068-72 [10223249.001]
  • [Cites] Hum Reprod Update. 1995 Mar;1(2):173-87 [15726771.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):30-5 [17220329.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):508-15 [17113137.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1383-9 [17416858.001]
  • [Cites] Biol Reprod. 2008 Jan;78(1):134-42 [17942799.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):383-9 [18586313.001]
  • [Cites] J Clin Lab Anal. 2009;23(4):244-8 [19623645.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1335-8 [20009886.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93 [11352859.001]
  • (PMID = 20850174.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105009-05; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / U01 CA086381-10; United States / NCI NIH HHS / CA / R01 CA54419; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R01 CA054419; United States / NCI NIH HHS / CA / 5U01 CA86381; United States / NCI NIH HHS / CA / R01 CA054419-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ NIHMS238531; NLM/ PMC2980911
  •  go-up   go-down


26. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO: Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. Ann Surg; 2009 May;249(5):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer.
  • OBJECTIVE: To compare transanal endoscopic microsurgery (TEMS) with conventional transanal excision (TAE) in terms of the quality of resection, local recurrence, and survival rates in patients with stage I rectal cancer.
  • We excluded patients with node-positive, metastatic, recurrent, previously irradiated, or snare-excised tumors.
  • In the TAE group, 52 (40%) of tumors were <5 cm from the anal verge (AV); in the TEMS group, only 1 (2%) (P = 0.0001).
  • In our multivariate analysis, the tumor distance from the anal verge, the resection margin status, the T stage, and the use of adjuvant therapy--but not the surgical technique (i.e., TEMS or TAE) itself--were independent predictors of local recurrence and DFS.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Patient Selection. Prognosis. Retrospective Studies. Survival Analysis


27. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


28. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol; 2005 Jan;7(1):32-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
  • In this phase 2 study, aprinocarsen was administered to patients with recurrent high-grade gliomas by continuous intravenous infusion (2.0 mg/kg/day for 21 days per month).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1996 Aug;50(2):236-42 [8700129.001]
  • [Cites] Glia. 1999 Feb 1;25(3):240-6 [9932870.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6001-4 [9497312.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3586-95 [10550158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3357-63 [10589745.001]
  • [Cites] Prog Neurobiol. 2001 Feb;63(3):321-36 [11115728.001]
  • [Cites] Curr Oncol Rep. 2000 Sep;2(5):445-53 [11122877.001]
  • [Cites] Neurosci Lett. 2001 Jan 19;297(3):163-6 [11137753.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):110-6 [11687282.001]
  • [Cites] Curr Oncol Rep. 2002 Jan;4(1):37-46 [11734112.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40 [11772309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1042-8 [11948111.001]
  • [Cites] Neurosci Lett. 2002 May 17;324(2):105-8 [11988338.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Aug;283(2):F309-18 [12110515.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2188-92 [12114419.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Anat. 2002 Jun;200(6):639-46 [12162731.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):96-103 [12672281.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Pharm Sci. 1985 Feb;74(2):229-31 [3989700.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):718-25 [3689368.001]
  • [Cites] Nature. 1988 Aug 25;334(6184):661-5 [3045562.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3215-7 [2720675.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 29;163(3):1377-83 [2783141.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):677-85 [2297708.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):10-9 [1637658.001]
  • [Cites] Pharmacol Ther. 1993 Sep;59(3):257-80 [8309991.001]
  • [Cites] J Biol Chem. 1994 Jun 10;269(23):16416-24 [7911467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762-6 [7972137.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] Anal Biochem. 1996 Mar 1;235(1):36-43 [8850544.001]
  • (PMID = 15701280.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA-26406; United States / NCI NIH HHS / CA / UO1CA-62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Phosphorothioate Oligonucleotides; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; FMT95051CQ / aprinocarsen
  • [Other-IDs] NLM/ PMC1871621
  •  go-up   go-down


29. Taniguchi M, Ookubo K, Ootsuka M, Akitake H, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Tsujie M, Konishi M, Ebisui C, Fujimoto T: [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
  • We have experienced a case of successful control of recurrent duodenal carcinoma receiving paclitaxel chemotherapy.
  • A 61-year-old woman with epigastralgia was diagnosed with pyloric gastric carcinoma upon upper gastrointestinal endoscopy and biopsy.
  • So, we additionally resected the anal edge.
  • And 13a, 13b, 12a, p lymph nodes were dissected for duodenal carcinoma.
  • Recurrence of the duodenal carcinoma was diagnosed in February 2007, and S-1 administration was begun.
  • Paclitaxel chemotherapy is effective for duodenal cancer.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037407.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Chrysos E, Athanasakis E, Vrekousis T, Almarashdah S, Fiorentini G, Xynos E, Zoras O: Abdominal and pelvic stop-flow chemotherapy. Effect of chemotherapeutic agents and tissue ischemia on rectoanal pressures. J Exp Clin Cancer Res; 2006 Sep;25(3):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stationary rectoanal manometry was performed within 24 hrs before and repeated 48 hrs after stop-flow chemotherapy in 7 consecutive patients with a history of locally advanced or recurrent abdominal and pelvic tumors.
  • Anal sphincter resting and squeeze pressures, rectal sensitivity, rectoanal inhibitory reflex and rectal volumes at which temporary and permanent urge to defecate were reported were examined.
  • Intraoperatively, changes in rectal and anal resting pressures before, during and after occlusion of the vessels and after administration of chemotherapeutic agent were as well recorded, analyzed and interpreted using ambulatory manometry.
  • Induction of anesthesia reduced distal and proximal anal resting pressures.
  • Intraoperative administration of chemotherapy did not further affect anal resting pressures during or after hypoxia.
  • Tissue hypoxia induced by vascular occlusion during stop-flow chemotherapy procedure, seems to be the only factor leading to a dramatic drop of anal pressures.
  • Anal pressures fully recover after reperfusion of the isolated area.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Anal Canal / drug effects. Antineoplastic Agents / pharmacokinetics. Chemotherapy, Cancer, Regional Perfusion / methods. Ischemia / pathology. Pelvic Neoplasms / drug therapy. Rectum / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17167968.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • Mean delay of cancer diagnosis was 11 months.
  • Thirteen of 15 patients with node-positive tumors died with recurrent disease following surgery.
  • Periodical cancer surveillance should be performed in all patients with long-standing perianal CD fistulae.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology


32. Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health; 2010 Apr;46(4 Suppl):S12-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cause of mortality related to human papillomavirus (HPV) infection is cervical cancer.
  • HPV is associated with a variety of cancers in men, including anal cancer and a subset of penile and oral cancers.
  • The incidence of anal and oral cancers related to HPV is increasing in the general population and is growing even faster among individuals who are immunocompromised because of human immunodeficiency virus (HIV) infection.
  • Likewise, anal HPV infection and anal intraepithelial neoplasia are very common throughout a wide range of ages in both HIV-negative and HIV-positive men who have sex with men.
  • Other HPV-related diseases of clinical importance in men include condylomata acuminata (genital warts) and recurrent respiratory papillomatosis.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Men's Health.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):468-76 [15243918.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):601-7 [15388997.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Int J Cancer. 1989 Aug 15;44(2):199-203 [2547727.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Med Virol. 1991 Mar;33(3):159-64 [1652616.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):827-35 [18657037.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2683-91 [18843010.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):59-70 [19050387.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):7-13 [19086813.001]
  • [Cites] J Adolesc Health. 2009 Jan;44(1):33-40 [19101456.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):536-46 [19191636.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6 [16030106.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):612-20 [16080082.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6 [16284377.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33 [16492924.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2645-54 [16790697.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] Emerg Infect Dis. 2007 Jan;13(1):28-41 [17370513.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Pediatr Infect Dis J. 2007 Mar;26(3):201-9 [17484215.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1128-36 [17955430.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1322-8 [17923869.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] J Infect Dis. 2008 Apr 1;197(7):957-66 [18429348.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Emerg Infect Dis. 2008 Jun;14(6):888-94 [18507898.001]
  • [Cites] Sex Transm Infect. 2008 Jun;84(3):161-6 [18339658.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):189-93 [11144896.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1467-74 [19443352.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1666-9 [8348498.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):470-4 [8651027.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1060-7 [8683637.001]
  • [Cites] Int J STD AIDS. 1996 May-Jun;7(3):197-200 [8799782.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] Sex Transm Dis. 1997 Nov;24(10):567-72 [9383844.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):744-54 [15599852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):351-7 [12196743.001]
  • [Cites] Sex Transm Infect. 2002 Jun;78(3):215-8 [12238658.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] J Infect Dis. 2004 Feb 15;189(4):677-85 [14767822.001]
  • [Cites] Med Microbiol Immunol. 2004 Feb;193(1):35-44 [12838415.001]
  • [ErratumIn] J Adolesc Health. 2010 Jun;46(6):614
  • (PMID = 20307839.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / CA088739-05; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-05; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS180665; NLM/ PMC2871537
  •  go-up   go-down


33. Kehe K, Balszuweit F, Emmler J, Kreppel H, Jochum M, Thiermann H: Sulfur mustard research--strategies for the development of improved medical therapy. Eplasty; 2008;8:e32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even decades after exposure, severe long-term effects like chronic obstructive lung disease, lung fibrosis, recurrent corneal ulcer disease, chronic conjunctivitis, abnormal pigmentation of the skin, and different forms of cancer have been diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2004 Jun;84(6):736-52 [15077120.001]
  • [Cites] Toxicol In Vitro. 2004 Oct;18(5):593-9 [15251176.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Oct 1;200(1):40-7 [15451306.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Jul;289(1):L67-74 [15778244.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):825-8 [15841169.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):421-40 [15864271.001]
  • [Cites] Cell Biol Toxicol. 2004 Nov;20(6):345-59 [15868479.001]
  • [Cites] Fundam Clin Pharmacol. 2005 Jun;19(3):297-315 [15910653.001]
  • [Cites] Toxicology. 2005 Oct 30;214(3):198-209 [16084004.001]
  • [Cites] Toxicol Sci. 2006 Apr;90(2):549-57 [16141436.001]
  • [Cites] J Appl Toxicol. 2006 Mar-Apr;26(2):126-31 [16252256.001]
  • [Cites] J Appl Toxicol. 2006 May-Jun;26(3):239-46 [16489579.001]
  • [Cites] Apoptosis. 2006 Sep;11(9):1545-59 [16738803.001]
  • [Cites] Biochem J. 1923;17(2):260-76 [16743181.001]
  • [Cites] J Nephrol. 2006 May-Jun;19 Suppl 10:S137-43 [16874728.001]
  • [Cites] Toxicology. 2006 Oct 3;227(1-2):21-35 [16935404.001]
  • [Cites] Cutan Ocul Toxicol. 2006;25(3):155-63 [16980241.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Oct;99(4):273-82 [17040211.001]
  • [Cites] Inhal Toxicol. 2007 Jun;19(8):657-65 [17510838.001]
  • [Cites] Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S134-49 [2419197.001]
  • [Cites] Beitr Gerichtl Med. 1989;47:533-8 [2818528.001]
  • [Cites] Basic Life Sci. 1986;38:357-63 [2943264.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Jan 14;134(1):227-32 [3080986.001]
  • [Cites] J Forensic Sci. 1987 Nov;32(6):1788-93 [3430139.001]
  • [Cites] Hepatology. 1985 Sep-Oct;5(5):876-82 [4029898.001]
  • [Cites] J Mol Biol. 1969 Jan 14;39(1):181-98 [5406275.001]
  • [Cites] JAMA. 1984 May 4;251(17):2255-61 [6368885.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5698-701 [6498832.001]
  • [Cites] Hum Exp Toxicol. 1995 Jul;14(7):547-53 [7576814.001]
  • [Cites] Mutat Res. 1993 Oct;294(3):235-45 [7692263.001]
  • [Cites] J Am Acad Dermatol. 1995 May;32(5 Pt 1):765-76 [7722023.001]
  • [Cites] J Leukoc Biol. 1994 Oct;56(4):436-43 [7930939.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7232-6 [8041772.001]
  • [Cites] Chem Biol Interact. 1994 Apr;91(1):39-49 [8194124.001]
  • [Cites] Xenobiotica. 1993 Jul;23(7):771-80 [8237059.001]
  • [Cites] South Med J. 1977 Mar;70(3):348-50 [847488.001]
  • [Cites] Chem Biol Interact. 1996 Mar 8;100(1):77-84 [8599857.001]
  • [Cites] Pharmacol Rev. 1996 Jun;48(2):289-326 [8804107.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Dec;141(2):568-83 [8975783.001]
  • [Cites] Microsc Res Tech. 1997 May 1;37(3):221-8 [9144634.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1835-40 [9157970.001]
  • [Cites] J Invest Dermatol. 1997 Jun;108(6):901-7 [9182819.001]
  • [Cites] Z Hautkr. 1977 Oct 15;52(20):1035-44 concl [919660.001]
  • [Cites] Surv Ophthalmol. 1997 May-Jun;41(6):461-6 [9220568.001]
  • [Cites] J Anal Toxicol. 1997 Jul-Aug;21(4):249-51 [9248939.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9711-7 [9545306.001]
  • [Cites] J Invest Dermatol. 1998 Jul;111(1):64-71 [9665388.001]
  • [Cites] Oncogene. 1998 Sep 10;17(10):1207-14 [9771963.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Apr 1;156(1):17-29 [10101095.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2174-81 [10232605.001]
  • [Cites] Trends Pharmacol Sci. 1999 Apr;20(4):171-81 [10322503.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 1):L754-62 [10330031.001]
  • [Cites] Mol Cell Biochem. 1999 Mar;193(1-2):137-48 [10331650.001]
  • [Cites] J Appl Toxicol. 1999 Sep-Oct;19(5):313-28 [10513676.001]
  • [Cites] Cell. 2000 Sep 1;102(5):647-55 [11007483.001]
  • [Cites] J Appl Toxicol. 2000 Sep-Oct;20(5):349-55 [11139165.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Jan 1;170(1):69-77 [11141358.001]
  • [Cites] J Appl Toxicol. 2000 Dec;20 Suppl 1:S129-32 [11428623.001]
  • [Cites] J Appl Toxicol. 2000 Dec;20 Suppl 1:S13-7 [11428624.001]
  • [Cites] J Appl Toxicol. 2000 Dec;20 Suppl 1:S141-4 [11428627.001]
  • [Cites] J Appl Toxicol. 2000 Dec;20 Suppl 1:S177-82 [11428632.001]
  • [Cites] J Appl Toxicol. 2000 Dec;20 Suppl 1:S63-72 [11428645.001]
  • [Cites] J Appl Toxicol. 2000 Dec;20 Suppl 1:S81-6 [11428649.001]
  • [Cites] Bioessays. 2001 Sep;23(9):795-806 [11536292.001]
  • [Cites] Int J Toxicol. 2001 Sep-Oct;20(5):281-96 [11766126.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1566-73 [11886524.001]
  • [Cites] Apoptosis. 2002 Aug;7(4):321-8 [12101391.001]
  • [Cites] J Appl Toxicol. 2002 Jul-Aug;22(4):257-62 [12210543.001]
  • [Cites] J Biochem Mol Toxicol. 2002;16(6):263-72 [12481301.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jul;4(7):552-65 [12838338.001]
  • [Cites] J Appl Toxicol. 2003 Jul-Aug;23(4):225-33 [12884405.001]
  • [Cites] J Occup Environ Med. 2003 Nov;45(11):1136-43 [14610394.001]
  • [Cites] J Appl Toxicol. 2004 Mar-Apr;24(2):107-13 [15052605.001]
  • (PMID = 18615149.001).
  • [ISSN] 1937-5719
  • [Journal-full-title] Eplasty
  • [ISO-abbreviation] Eplasty
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2431646
  •  go-up   go-down


34. Giuliano AR, Anic G, Nyitray AG: Epidemiology and pathology of HPV disease in males. Gynecol Oncol; 2010 May;117(2 Suppl):S15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, recurrent respiratory papillomatosis is a rare disease most often associated with HPV types 6 and 11.
  • For example, there is increasing incidence of anal cancer in western countries; however, there are limited data on its primary cause, anal canal HPV infection.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):362-71 [19133808.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] J Clin Virol. 2009 Feb;44(2):111-4 [19097933.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] Eur J Cancer Prev. 2009 Jun;18(3):236-9 [19491611.001]
  • [Cites] Int J STD AIDS. 2009 Aug;20(8):557-60 [19625588.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):330-5 [19342375.001]
  • [Cites] J Clin Pathol. 2009 Oct;62(10):870-8 [19706632.001]
  • [Cites] Sex Transm Infect. 2009 Dec;85(7):499-502 [19837728.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer Causes Control. 2001 Apr;12(3):267-77 [11405332.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1211-8 [11583947.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] J Infect Dis. 2002 Aug 15;186(4):462-9 [12195372.001]
  • [Cites] Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S210-24 [12353208.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Lancet. 1985 Apr 27;1(8435):943-6 [2859410.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1306-8 [3120988.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):178-84 [2384268.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):504-9 [1995481.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):19-24 [8380060.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Infect Dis. 1994 Sep;170(3):682-5 [8077728.001]
  • [Cites] Genitourin Med. 1994 Aug;70(4):240-6 [7959707.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1068-75 [8683638.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S82-90 [15753016.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1128-36 [17955430.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1137-45 [17955431.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1146-52 [17955432.001]
  • [Cites] J Infect Dis. 2007 Nov 15;196(10):1447-54 [18008222.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Feb;265(2):147-51 [18046565.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Sex Transm Dis. 2008 Apr;35(4):357-60 [18360316.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S6-13 [18499914.001]
  • [Cites] J Infect Dis. 2008 Jun 15;197(12):1676-84 [18426367.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):827-35 [18657037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2683-91 [18843010.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):7-13 [19086813.001]
  • (PMID = 20138345.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803; United States / NCI NIH HHS / CA / R03 CA134204; United States / NCI NIH HHS / CA / R01CA098803; United States / NCI NIH HHS / CA / R03CA134204-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS645179; NLM/ PMC4254924
  •  go-up   go-down


35. Zbar AP, Shenoy RK, Chiappa A: Extended abdominoperineal resection in women: the Barbadian experience. Int Semin Surg Oncol; 2007;4:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: We report our results of a selective approach to primary direct appositional vaginal repair versus transverse rectus abdominis flap repair (TRAM) in patients with extensive rectal/anal cancer or in cases with primary cancer of cervix, vagina or vulva involving the anal canal and anal sphincters.
  • Exenterative procedures were performed in 2 cases of primary vaginal cancer, following Wertheim hysterectomy for carcinoma of the cervix with recurrence after radiation and in 2 further cases of anal cancer with extensive pelvic recurrence after primary chemoradiation.
  • Fifteen cases are alive on follow-up with no evidence of disease; 2 patients who had recurrent carcinoma of the cervix and who underwent TRAM flap reconstruction, have recurrent disease after 5 and 6 months of follow-up, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 May;97(2):596-601 [15863165.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2229-35 [8918419.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):476-81; discussion 481-2 [15714245.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):389-94 [15657636.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):398-403 [15297179.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):610-4 [15196852.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):424-6 [14760771.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):27-33 [14699030.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):39-45 [12468340.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1144-50 [12209702.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):239-45; discussion 245-8 [11852339.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Plast Reconstr Surg. 1983 Dec;72(6):751-65 [6647599.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):890-6 [8076488.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):261-8 [16426668.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):542-8 [15882183.001]
  • (PMID = 17214895.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779795
  •  go-up   go-down


36. Rondeau V, Mathoulin-Pélissier S, Tanneau L, Sasco AJ, Macgrogan G, Debled M: Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death. BMC Cancer; 2010;10:697
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death.
  • BACKGROUND: In the setting of recurrent events, research studies commonly count only the first occurrence of an outcome in a subject.
  • The objective is to jointly identify prognostic factors associated with locoregional recurrences (LRR), contralateral breast cancer, distant metastases (DM), other primary cancer than breast and breast cancer death and to evaluate the correlation between these events.
  • METHODS: Patients (n = 919) with a primary invasive breast cancer and treated in a cancer center in South-Western France with breast-conserving surgery from 1990 to 1994 and followed up to January 2006 were included.
  • Several types of non-independent events could be observed for the same patient: a LRR, a contralateral breast cancer, DM, other primary cancer than breast and breast cancer death.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Stat Med. 1998 Sep 15;17(17):1973-88 [9777690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):25-38 [9989511.001]
  • [Cites] Breast Cancer Res Treat. 1999 Mar;54(1):83-9 [10369084.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):229-35 [15720997.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1319-22 [15719436.001]
  • [Cites] Stat Med. 2006 Oct 30;25(20):3518-33 [16345026.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1802-7 [17533401.001]
  • [Cites] Biostatistics. 2007 Oct;8(4):708-21 [17267392.001]
  • [Cites] Stat Med. 2008 Mar 15;27(6):922-36 [17551931.001]
  • [Cites] Stat Med. 2008 Jun 30;27(14):2665-83 [17910008.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(2):401-8 [19148746.001]
  • [Cites] Comput Methods Programs Biomed. 2005 Nov;80(2):154-64 [16144730.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):35-41 [16333848.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):351-6 [16314086.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2285-92 [16342146.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):62-8 [16875939.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):998-1002 [11093827.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):488-9 [11287433.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2134-42 [12001109.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):926-33 [12569592.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):38-43 [12589868.001]
  • [Cites] Lifetime Data Anal. 2003 Jun;9(2):139-53 [12735493.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1441-6 [15467033.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):19-27 [7666458.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):52-7 [8558220.001]
  • [Cites] Int J Epidemiol. 1998 Oct;27(5):743-50 [9839728.001]
  • (PMID = 21194468.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3019213
  •  go-up   go-down


37. Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY: Mucinous carcinoma in Crohn's disease originating in a fistulous tract. World J Gastrointest Oncol; 2010 Jul 15;2(7):307-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma in Crohn's disease originating in a fistulous tract.
  • An 18-year-old male with extensive small and large bowel involvement with Crohn's disease developed recurrent peri-rectal fistulous disease that persisted for more than a decade despite pharmacological and surgical therapy as well as later therapy with biological agents.
  • Eventually, an extensive and difficult-to-detect mucinous carcinoma developed in the fistulous tract.
  • Although fistula cancer is rarely described in Crohn's disease, use of immunosuppressant and biological agents may play an initiating or exacerbating role in its development or progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160662.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999135
  • [Keywords] NOTNLM ; Adalimumab / Anal fistula / Anorectal adenocarcinoma / Crohn’s disease / Fistula carcinoma / Infliximab / Tumor necrosis factor antibodies
  •  go-up   go-down


38. Ota Y, Takagi Y, Osaka Y, Hoshino S, Shinohara M, Sudo H, Tsuchida A, Aoki T: [A case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stent-in-stent placement was effective]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2042-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stent-in-stent placement was effective].
  • OBJECTIVES: We report one case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stenting was effective and good QOL was achieved.
  • In July 2000, the patient underwent total gastrectomy.Roux-en Y reconstruction with a diagnosis of gastric cancer.
  • Based on a biopsy of the stenosis, a diagnosis of post-operative recurrent gastric cancer was made.
  • METHOD: After a guide wire was endoscopically inserted and a good passage on the anal side of the stenosis was confirmed, a stent was placed.
  • CONCLUSION: Stenting is relatively simple and less invasive, which is useful for the improvement of QOL and in recurrent cases as well.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106517.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E: Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia; 2006 Jan;8(1):38-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer.
  • RESULTS: TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells.
  • Very interestingly, specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), whereas it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023).
  • CONCLUSION: TOP2A mRNA and protein expression in ovarian cancer exhibits specific patterns in tumor epithelial and adjacent stromal cells, which are differentially modulated after platinum-based chemotherapy.
  • These data support the recently discovered importance of the stromal compartment in tumor progression and suggest that tumor stromal cells might be relevant to the development of chemotherapy resistance in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):257-74 [9748618.001]
  • [Cites] J Med Invest. 2005 Feb;52(1-2):41-8 [15751272.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):921-7 [10970695.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):666-72 [11041055.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):54-9 [11163151.001]
  • [Cites] Pathobiology. 2000;68(4-5):209-14 [11279348.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):107-38 [11385772.001]
  • [Cites] Breast Cancer Res. 2001;3(4):224-9 [11434873.001]
  • [Cites] Int J Gynecol Cancer. 2001;11 Suppl 1:7-11 [11488996.001]
  • [Cites] Int J Gynecol Cancer. 2001;11 Suppl 1:52-6 [11489004.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2925-32 [11712788.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):691-7 [11895897.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Zentralbl Gynakol. 2002 Mar;124(3):176-83 [12070798.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Nov;34(11):1401-14 [12200035.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1673-9 [12738720.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1403-10 [14973057.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):887-95 [14984957.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):19-31 [15034864.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 2):2569-81 [3025219.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] NCI Monogr. 1987;(4):61-71 [2819733.001]
  • [Cites] Adv Cancer Res. 1988;50:159-96 [3287842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5 [2556712.001]
  • [Cites] Cancer Res. 1991 Nov 1;51(21):5915-20 [1682037.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):479-84 [8759604.001]
  • [Cites] Nucleic Acids Res. 1996 Nov 15;24(22):4464-70 [8948636.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):275-88 [9748627.001]
  • [Cites] Gene. 1998 Oct 23;221(2):255-66 [9795238.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1329-33 [9809560.001]
  • [Cites] J Obstet Gynaecol Res. 1998 Dec;24(6):447-51 [10063241.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:43-50 [10219452.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3206-14 [10397267.001]
  • [Cites] J Histochem Cytochem. 1997 Feb;45(2):251-63 [9016314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Mol Pathol. 1997 Oct;50(5):247-53 [9497914.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54 [9748545.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • (PMID = 16533424.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC1584288
  •  go-up   go-down


40. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


41. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR: Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res; 2008 Jun 1;14(11):3283-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.
  • PURPOSE: The cancer/germline antigen NY-ESO-1 is variably expressed in epithelial ovarian cancer (EOC), with most tumors showing low or heterogeneous expression, which limits patient responses to NY-ESO-1 vaccine therapy.
  • These findings support a novel chemoimmunotherapy approach using decitabine to augment NY-ESO-1 vaccine therapy for treatment of recurrent EOC.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Mol Pharmacol. 2004 Jan;65(1):18-27 [14722233.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4472-80 [15231656.001]
  • [Cites] Immunogenetics. 1995;42(4):282-90 [7672823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7149-53 [8692960.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1245-52 [9515812.001]
  • [Cites] Cancer J Sci Am. 1999 Jan-Feb;5(1):20-5 [10188057.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7327-35 [10523621.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9167-71 [15604288.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7751-62 [16140943.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7763-74 [16140944.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10118-26 [16497664.001]
  • [Cites] Mol Cancer Res. 2006 May;4(5):339-49 [16687489.001]
  • [Cites] Adv Cancer Res. 2006;95:1-30 [16860654.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5777-85 [17020984.001]
  • [Cites] Oncogene. 2006 Nov 2;25(52):6975-85 [16715135.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Histol Histopathol. 2007 Sep;22(9):1005-15 [17523078.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4394-403 [17260018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42 [17652518.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5553-63 [17353906.001]
  • [Cites] Epigenetics. 2006 Jul-Sep;1(3):116-20 [17786175.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):777-84 [17957795.001]
  • [Cites] Cancer Immun. 2007;7:21 [18095639.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6076-83 [14522938.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6484-8 [14528272.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • (PMID = 18519754.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116674; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R01 CA116674-02; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R01CA11674; United States / NCI NIH HHS / CA / CA116674-04; United States / NCI NIH HHS / CA / CA116674-01A1; United States / NCI NIH HHS / CA / CA116674-02; United States / NCI NIH HHS / CA / R01 CA116674-03; United States / NCI NIH HHS / CA / R01 CA116674-01A1; United States / NCI NIH HHS / CA / R01 CA116674-04; United States / NCI NIH HHS / CA / 5T32CA009072; United States / NCI NIH HHS / CA / T32 CA009072; United States / NCI NIH HHS / CA / CA116674-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ NIHMS182570; NLM/ PMC2835568
  •  go-up   go-down


42. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol; 2008 Mar;108(3):619-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate receptor alpha as a tumor target in epithelial ovarian cancer.
  • The goal of this study is to improve historical data that lack specific information about FRalpha expression in rare histological subtypes, primary disease versus metastatic foci, and recurrent disease.
  • METHODS: FRalpha expression was analyzed by immunohistochemistry on 186 primary and 27 recurrent ovarian tumors, including 24 pairs of samples obtained from the same individuals at diagnosis and at secondary debulking surgery.
  • RESULTS: FRalpha expression was apparent in 134 of 186 (72%) primary and 22 of 27 (81.5%) recurrent ovarian tumors.
  • In 21 of 24 (87.5%) matched specimens, recurrent tumors reflected the FRalpha status detected at diagnosis.
  • New findings from this study show that FRalpha expression is maintained on metastatic foci and recurrent tumors, suggesting that novel folate-targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2003 May;44(5):700-7 [12732670.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):52-7 [17582475.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1085-97 [15094208.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1219-31 [15094217.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Aug;287(2):C517-26 [15102609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6 [2062838.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5329-38 [1717147.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3396-401 [1596899.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5791-6 [8242637.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] Int J Cancer Suppl. 1994;8:89-95 [8194901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61 [7568072.001]
  • [Cites] APMIS. 1995 Sep;103(9):663-70 [7488388.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):121-6 [9583724.001]
  • [Cites] Arch Biochem Biophys. 1999 Jun 15;366(2):183-91 [10356282.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1505-12 [15634643.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Curr Pharm Biotechnol. 2005 Apr;6(2):131-50 [15853692.001]
  • [Cites] J Pharm Sci. 2005 Oct;94(10):2135-46 [16136558.001]
  • [Cites] Front Biosci. 2006;11:506-19 [16146749.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2168-72 [16172227.001]
  • [Cites] Curr Oncol Rep. 2005 Nov;7(6):451-8 [16221382.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Feb;21(1):49-60 [16480331.001]
  • [Cites] Cancer. 2006 May 1;106(9):1933-9 [16572412.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36 [16331500.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):603-9 [16704197.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1994-2004 [16767218.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1007-16 [16763819.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4254-61 [16908932.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8 [17062694.001]
  • [Cites] Cancer Immun. 2007;7:6 [17346028.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):141-52 [17333345.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2557-67 [17473184.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):938-42 [17487842.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1585-92 [17551919.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Gene Ther. 2003 Jun;10(12):1018-25 [12776159.001]
  • (PMID = 18222534.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA80628; United States / NCI NIH HHS / CA / K12 CA090628-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS123756; NLM/ PMC2707764
  •  go-up   go-down


44. Uchikoshi F, Nishida T, Ueshima S, Nakahara M, Matsuda H: Laparoscope-assisted anal sphincter-preserving operation preceded by transanal procedure. Tech Coloproctol; 2006 Mar;10(1):5-9; discussion 9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscope-assisted anal sphincter-preserving operation preceded by transanal procedure.
  • BACKGROUND: Transanal intersphincteric resection (ISR) was introduced and has been increasingly performed as an ultimate surgical treatment for extremely low rectal cancer.
  • METHODS: Between December 2003 and June 2004, we performed laparoscope-assisted ISR for two patients with very low rectal cancer and total colectomy for two patients with ulcerative colitis complicated by colorectal cancer.
  • All patients showed favorable recovery including postoperative anal function with no complication or recurrent disease.
  • CONCLUSIONS: This procedure is feasible and has favorable short-term results for radical treatment of very low rectal disease, while preserving anal function.
  • [MeSH-major] Anal Canal / surgery. Proctoscopy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528490.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH: The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ; 2010 Mar;13(1):110-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A transmission dynamic model was used to assess the epidemiological and economic impact of a quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine in preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN 2/3), CIN 1 and genital warts in Hungary.
  • RESULTS: The model projected that at year 100, both strategies could reduce the incidence of HPV 6/11/16/18-related cervical cancer, CIN 2/3, CIN 1 and genital warts cases among Hungarian women by 90%, 90%, 85% and 93%, respectively.
  • Twenty-five years after the introduction of HPV vaccination in the population, routine vaccination of girls by the age of 12 reduced the cumulative number of cases of cervical cancer, CIN 2/3, CIN 1 and genital warts by 685, 13,473, 3,423 and 163,987, respectively.
  • KEY LIMITATIONS: The model did not account for the health and economic impact of other HPV diseases which may result from HPV 16, 18, 6, and 11 infections such as vaginal, vulvar, penile, anal and head-neck cancers, and recurrent respiratory papillomatosis.
  • CONCLUSION: A quadrivalent HPV vaccination programme can reduce the incidence of cervical cancer, CIN and genital warts in Hungary at a cost-per-QALY ratio within the range defined as cost effective.


46. Nelson RS, Boland E, Ewing BM, Blatchford GJ, Ternent C, Shashidharan M, Tran NA, Beaty J, Thorson AG: Permanent diversion rates after neoadjuvant therapy and coloanal anastomosis for rectal cancer. Am J Surg; 2009 Dec;198(6):765-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Permanent diversion rates after neoadjuvant therapy and coloanal anastomosis for rectal cancer.
  • BACKGROUND: The aim of this study was to assess the rate of permanent diversion in patients undergoing coloanal anastomosis after neoadjuvant therapy for rectal cancer.
  • METHODS: We performed a retrospective review of patients with rectal cancer who underwent a total mesorectal excision of a tumor within 9 cm of the anal verge.
  • The average tumor distance from the anal verge was 7 cm (range, 4-9 cm).
  • Twenty-five patients (12%) had recurrent disease, 16 of these were local recurrence.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19969127.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Shah SP, Cheung KJ Jr, Johnson NA, Alain G, Gascoyne RD, Horsman DE, Ng RT, Murphy KP: Model-based clustering of array CGH data. Bioinformatics; 2009 Jun 15;25(12):i30-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MOTIVATION: Analysis of array comparative genomic hybridization (aCGH) data for recurrent DNA copy number alterations from a cohort of patients can yield distinct sets of molecular signatures or profiles.
  • This can be due to the presence of heterogeneous cancer subtypes within a supposedly homogeneous population.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2006 Sep;16(9):1149-58 [16899652.001]
  • [Cites] Nucleic Acids Res. 2008 Feb;36(2):e13 [18187509.001]
  • [Cites] Genome Biol. 2007;8(10):R215 [17925008.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):553-63 [18385729.001]
  • [Cites] Blood. 2009 Jan 1;113(1):137-48 [18703704.001]
  • [Cites] Biometrics. 2009 Mar;65(1):19-29 [18479479.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Mar;39(3):195-204 [14732921.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1827-37 [15229187.001]
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 1993;1:47-55 [7584370.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2667-75 [15571950.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Sep;26(9):1154-66 [15742891.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Bioinformatics. 2006 Apr 1;22(7):849-56 [16434445.001]
  • [Cites] Bioinformatics. 2006 Jul 15;22(14):e431-9 [16873504.001]
  • [Cites] Sci Am. 2007 Mar;296(3):50-7 [17348159.001]
  • [Cites] Nucleic Acids Res. 2007;35(6):2013-25 [17341461.001]
  • [Cites] Bioinformatics. 2007 Jul 1;23(13):i450-8 [17646330.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108 [17823929.001]
  • [Cites] J Pathol. 2007 Feb;211(3):286-95 [17154249.001]
  • (PMID = 19478003.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2687959
  •  go-up   go-down


48. Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J: c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology; 2008 Jan;149(1):108-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of the MIS type II receptor (MISRII) in ovarian cancer cells and the ability of MIS to inhibit proliferation of these cells suggest that MIS might be a promising therapeutic for recurrent ovarian cancer.
  • Moreover, treatment of mouse ovarian cancer cells with a combination of SP600125 and paclitaxel, an established chemotherapeutic agent used in the treatment of ovarian cancer, or with MIS enabled inhibition of cell proliferation at a lower dose than with each treatment alone.
  • These results offer a strong rationale for testing the therapeutic potential of SP600125, alone or in combination with already established drugs, in the treatment of recurrent ovarian cancer with a much-needed decrease in the toxic side effects of currently employed therapeutic agents.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2001 Oct;22(5):657-74 [11588147.001]
  • [Cites] Nat Cell Biol. 2001 Aug;3(8):708-14 [11483955.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):168-72 [11774260.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98 [11820299.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4883-91 [11729207.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2640-6 [12171896.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36024-31 [12130649.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):408-10 [12368913.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1389-97 [12649204.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4314-32 [12853969.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9 [14656475.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9075-86 [14663486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6 [14671316.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):259-64 [14573624.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2185-95 [15141161.001]
  • [Cites] J Surg Res. 1977 Aug;23(2):141-8 [886843.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Genes Dev. 1993 Nov;7(11):2135-48 [8224842.001]
  • [Cites] Genes Dev. 1996 Oct 15;10(20):2577-87 [8895659.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Cell. 1994 Nov 4;79(3):415-25 [7954809.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1429-32 [8999807.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1677-81 [8999845.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1844-54 [9528756.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3091-100 [9606191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6 [15618407.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3219-24 [15728372.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Apr;313(1):325-32 [15626722.001]
  • [Cites] Anal Biochem. 2006 Feb 1;349(1):78-86 [16307714.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2072-81 [16287090.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1593-8 [16533786.001]
  • [Cites] Development. 2006 Jun;133(12):2359-69 [16687449.001]
  • [Cites] J Bone Miner Res. 2006 May;21(5):674-83 [16734382.001]
  • [Cites] J Med Chem. 2006 Jun 15;49(12):3563-80 [16759099.001]
  • [Cites] Oncogene. 2006 Aug 10;25(35):4857-66 [16547493.001]
  • [Cites] Genes Cells. 2006 Sep;11(9):983-92 [16923120.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2382-91 [16740653.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31 [17088539.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):160-5 [8536608.001]
  • [Cites] EMBO J. 2000 Apr 17;19(8):1745-54 [10775259.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27973-8 [10854429.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28371-9 [10874041.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):936-45 [11376112.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):946-59 [11376113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6 [11717429.001]
  • (PMID = 17947357.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA017393; United States / NCI NIH HHS / CA / CA17393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracenes; 0 / Bone Morphogenetic Proteins; 0 / Enzyme Inhibitors; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anthra(1,9-cd)pyrazol-6(2H)-one; 0 / anti-Mullerian hormone receptor; 80497-65-0 / Anti-Mullerian Hormone; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2194615
  •  go-up   go-down


49. Mohler JL: A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab; 2008 Apr;22(2):357-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for the androgen-receptor in clinically localized and advanced prostate cancer.
  • Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic hyperplasia (BPH).
  • High levels of AR and AR-regulated gene expression indicate a central role for AR in growth regulation of castration-recurrent CaP.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 1999 Jan 1;35(1):2-10 [10554175.001]
  • [Cites] Endocr Relat Cancer. 1999 Dec;6(4):487-502 [10730903.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):423-7 [11212224.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3550-5 [11325816.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4315-9 [11389051.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97 [11717329.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):219-26 [11786415.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Endocr Relat Cancer. 2002 Mar;9(1):61-73 [11914183.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Curr Urol Rep. 2002 Feb;3(1):67-74 [12084222.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):20-4 [12559071.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] J Urol. 2003 Nov;170(5):1817-21 [14532783.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):146-50 [14747438.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):75-9 [15158050.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):928-34 [15223964.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Dec;16(6):400-14 [7536003.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Lab Invest. 1995 Aug;73(2):302-5 [7637331.001]
  • [Cites] Prostate. 1996 Apr;28(4):251-65 [8602401.001]
  • [Cites] J Urol. 1998 Mar;159(3):641-9 [9474117.001]
  • [Cites] J Urol. 1998 Feb;159(2):548-54 [9649289.001]
  • [Cites] Mol Carcinog. 1993;7(3):165-79 [8489712.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):21-7 [1845164.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4096-102 [7518349.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):889-95 [9816246.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2511-5 [10363963.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):411-9 [10453285.001]
  • [Cites] Prostate. 2005 Apr 1;63(1):19-28 [15378523.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):309-19 [17045208.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10594-602 [17079484.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43 [17494760.001]
  • [Cites] Prostate. 2008 Jun 1;68(8):830-8 [18324648.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] J Natl Cancer Inst. 1980 Aug;65(2):311-6 [6931251.001]
  • [Cites] J Urol. 1984 Apr;131(4):694-700 [6708184.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):382-8 [2578085.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2351-6 [2421868.001]
  • [Cites] Science. 1988 Apr 15;240(4850):324-6 [3353726.001]
  • [Cites] Science. 1988 Apr 15;240(4850):327-30 [3353727.001]
  • [Cites] Arch Pathol Lab Med. 1988 Aug;112(8):787-90 [3395214.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1265-75 [3216866.001]
  • [Cites] J Steroid Biochem. 1989;34(1-6):311-3 [2626023.001]
  • [Cites] J Pathol. 1990 Apr;160(4):329-32 [2193135.001]
  • [Cites] Ann N Y Acad Sci. 1990;595:53-66 [1695829.001]
  • [Cites] Prostate. 1990;17(4):293-300 [1701248.001]
  • [Cites] Int J Cancer. 1991 May 10;48(2):189-93 [1708363.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3057-64 [1710537.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2574-80 [7680949.001]
  • [Cites] J Urol. 1993 May;149(5):1015-9 [7683339.001]
  • (PMID = 18471792.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA077739-100006; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA 77739; United States / NCI NIH HHS / CA / P01 CA077739-100006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen
  • [Number-of-references] 76
  • [Other-IDs] NLM/ NIHMS52370; NLM/ PMC2799036
  •  go-up   go-down


50. Huang JS, Lin CM, Cheng YC, Hung KL, Chien CC, Chen SK, Chang CJ, Chen CW, Huang CJ: A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect. J Mol Med (Berl); 2009 Jun;87(6):613-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with sporadic hemangioblastoma, C-terminally truncated VHL protein or a large deletion in the VHL gene, and the T allele were 18.0-fold more likely to develop recurrent disease.
  • Taken together, individuals with mutated VHL are more likely to be affected by familial or recurrent sporadic hemangioblastoma when carrying the M/T or T/T genotype at codon 381 of vitronectin.

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):256-8 [9399847.001]
  • [Cites] Cancer Sci. 2006 May;97(5):400-5 [16630138.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3880-93 [16739133.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):121-3 [15608011.001]
  • [Cites] J Neurooncol. 2001 May;52(3):241-7 [11519854.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25733-41 [10823831.001]
  • [Cites] J Pathol. 2000 Nov;192(3):280-8 [11054709.001]
  • [Cites] Biochemistry. 1985 Apr 23;24(9):2368-74 [2581612.001]
  • [Cites] J Clin Invest. 2008 Apr;118(4):1367-79 [18340378.001]
  • [Cites] J Cell Sci. 1995 Apr;108 ( Pt 4):1553-61 [7542256.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):694-703 [8552098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11435-8 [13679585.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4568-74 [11134110.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6331-6 [17085642.001]
  • [Cites] Adv Anat Pathol. 2008 May;15(3):165-71 [18434768.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):273-5 [15980980.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):307-16 [11433393.001]
  • [Cites] Nat Protoc. 2006;1(2):812-23 [17406312.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] FEBS Lett. 1990 Aug 20;269(1):221-5 [1696913.001]
  • [Cites] Ann Neurol. 2004 May;55(5):721-8 [15122713.001]
  • [Cites] J Cell Sci. 2005 Jan 15;118(Pt 2):301-11 [15615775.001]
  • [Cites] Eur J Clin Invest. 2007 Jun;37(6):492-500 [17537157.001]
  • [Cites] Anal Biochem. 2000 Dec 1;287(1):55-64 [11078583.001]
  • [Cites] Neurosurgery. 2005 Mar;56(3):503-9; discussion 503-9 [15730575.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 May;70(5):644-8 [11309459.001]
  • [Cites] Anal Chem. 1995 Apr 15;67(8):1426-36 [7741214.001]
  • [Cites] Arch Neurol. 1976 Jun;33(6):435-41 [945725.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):74-83 [9062583.001]
  • [Cites] J Biol Chem. 1990 Jun 15;265(17):9778-81 [1693616.001]
  • [Cites] Biochem J. 1991 Mar 1;274 ( Pt 2):387-94 [1706595.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):504-8 [9458097.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Mar;80(5):1362-6 [6187012.001]
  • [Cites] Am J Hum Genet. 1998 Oct;63(4):1025-35 [9758595.001]
  • [Cites] J Med Genet. 2002 Jul;39(7):E38 [12114495.001]
  • [Cites] Brain Tumor Pathol. 2004;21(2):75-82 [15700837.001]
  • [Cites] Radiology. 1995 Mar;194(3):629-42 [7862955.001]
  • [Cites] Int J Clin Oncol. 2004 Aug;9(4):283-7 [15375704.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1937-40 [14604959.001]
  • [Cites] Chin Med J (Engl). 2004 Apr;117(4):552-7 [15109448.001]
  • [Cites] Development. 2001 May;128(9):1481-92 [11290288.001]
  • [Cites] Ann Neurol. 2004 Feb;55(2):236-40 [14755727.001]
  • [Cites] Neurosurg Clin N Am. 2006 Jan;17(1):37-44 [16448906.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3624-6 [15908674.001]
  • [Cites] Clin Diagn Lab Immunol. 2001 Jan;8(1):105-11 [11139202.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Apr;28(2):142-6 [11972801.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3067-74 [12202531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):620-4 [11209058.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10 (7):763-7 [11257110.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • (PMID = 19288063.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vitronectin; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


51. Sheng XH, Gao CF, Ji XQ, Wei D, Zheng GB: [Comparative study of recurrent colon cancer and recurrent rectal cancer after radical resection]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jun;13(6):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study of recurrent colon cancer and recurrent rectal cancer after radical resection].
  • OBJECTIVE: To explore the difference in tumor biological behaviors and prognosis between recurrent colon cancer and recurrent rectal cancer after radical operation.
  • METHODS: Complete clinical and follow-up data of 132 patients with colorectal cancer developed recurrence,including 36 colon cancers and 96 rectal cancers, after curative resection were retrospectively analyzed and compared with respect of clinical pathological features and prognosis between colon and rectal cancer.
  • RESULTS: Significant differences were found in primary tumor gross type, histological type, tumor differentiation and lymph node metastasis between colon and rectal cancer(P<0.05).
  • Colon cancer recurred earlier than rectal cancer after radical surgery with the median time to recurrence being 14.0 months and 21.5 months, respectively(P=0.028).
  • The difference in multiple sites recurrence was also found between colon(n=16, 44.4%) and rectal cancer(n=65, 67.7%)(P=0.014).
  • The 3-year survival rate of recurrent rectal cancer was better than that of colon cancer (24.8% vs 15.6%, P=0.026).
  • CONCLUSION: There are some differences in tumor biological behaviors between colon and rectal cancer, and the prognosis of rectal cancer with recurrence is better than that of colon cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20577916.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • Despite treatment, three patients progressed to invasive cancer (1.2 percent).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA, European Association of Urology (EAU) Guidelines Group on Penile Cancer: EAU penile cancer guidelines 2009. Eur Urol; 2010 Jun;57(6):1002-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAU penile cancer guidelines 2009.
  • CONTEXT: Squamous cell carcinoma (SCC) of the penis is a relatively rare but ominous disease.
  • Similarities in etiology with SCC of the head and neck, the female genitalia, and the anal canal have been found.
  • Adjuvant and neoadjuvant chemotherapy showed promising results in patients with advanced or recurrent disease.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Quality of Life / psychology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20163910.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Ozturk M, Kordan Y, Cangul H, Dogan HS, Kilicarslan H, Vuruskan H, Oktay B: Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children. Int Urol Nephrol; 2008;40(3):563-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urokinase concentrations are lower and urokinase gene 3'-UTR T/C polymorphism is higher in patients with recurrent stones.
  • Our aim was to investigate the role of urokinase gene 3'-UTR T/C polymorphism in childhood recurrent stone disease.
  • MATERIAL AND METHODS: A control group of 40 healthy children having no history of stone formation (group 1) (mean age 10.5+/-4.2 years), 40 children (mean age 10.5+/-4.33 years) who had calcium oxalate stones for the first time (group 2), and 40 patients (mean age 11.2+/-3.8 years) with recurrent calcium oxalate stone disease (group 3) were included in the study.
  • CONCLUSIONS: Urokinase 3'-UTR T/C gene polymorphism seems to appear more commonly in children with recurrent calcium oxalate stone disease than in healthy children and in those with stones for the first time.
  • These results suggest that the urokinase gene might play a role in childhood recurrent calcium oxalate stone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Hypotheses. 1997 Jul;49(1):57-9 [9247909.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2846-52 [2492525.001]
  • [Cites] Urol Res. 1992;20(1):41-4 [1531276.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):963-8 [9120402.001]
  • [Cites] Histochem Cell Biol. 1996 Jan;105(1):53-60 [8824906.001]
  • [Cites] Cell. 1993 Jan 15;72(1):19-28 [8380757.001]
  • [Cites] Kidney Int. 1996 Nov;50(5):1706-12 [8914040.001]
  • [Cites] Urol Int. 2006;77(1):81-4 [16825821.001]
  • [Cites] Urol Res. 1995;23(5):335-8 [8839391.001]
  • [Cites] Ann Intern Med. 1989 Dec 15;111(12):1006-9 [2688503.001]
  • [Cites] Nature. 1999 Oct 21;401(6755):734 [10548090.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1141-52 [1528210.001]
  • [Cites] BJU Int. 2001 Sep;88(4):432-6 [11564035.001]
  • [Cites] Urology. 2002 Mar;59(3):458-61 [11880102.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jul;82(13):4448-52 [2989821.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Dec;20(4):569-72 [11876553.001]
  • [Cites] Med Hypotheses. 1991 Dec;36(4):368-70 [1809856.001]
  • [Cites] BJU Int. 2001 Feb;87(3):168-71 [11167636.001]
  • [Cites] J Endourol. 2006 Feb;20(2):157-60 [16509805.001]
  • [Cites] Urol Res. 2001 Apr;29(2):94-7 [11396735.001]
  • [Cites] Thromb Haemost. 1997 Mar;77(3):434-5 [9065988.001]
  • [Cites] J Clin Lab Anal. 2004;18(5):276-9 [15356878.001]
  • (PMID = 18240004.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 2612HC57YE / Calcium Oxalate; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


55. Roncucci L: Local recurrences of rectal cancer. Minerva Chir; 2005 Jun;60(3):167-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrences of rectal cancer.
  • Data from cancer registries show that incidence of rectal cancer is still high in Italy, while mortality rates are slightly decreasing in most recent years.
  • The rectum may be defined as the tract of the large bowel distal to 12 cm from the anal verge.
  • Pelvic recurrence is evident as a regrowth of cancer in and around the tumor bed.
  • A wide range of recurrence rates after operation for rectal cancer are reported, spanning from 3% to over 30%.
  • This technique has decreased dramatically recurrence rates of rectal cancer, though increasing the risk of local complications.
  • Management of locally recurrent tumors is still unsatisfactory and surgery is feasible only in less than 10% of cases.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985992.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 80
  •  go-up   go-down


56. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY: Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest; 2009 Jun;27(5):549-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
  • To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology.
  • Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer.
  • Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1128-36 [16489065.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] JAMA. 2006 May 17;295(19):2234-8 [16705097.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3973-8 [16921049.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2317-21 [17119066.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):665-74; discussion 674 [16956712.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] J Urol. 2001 Jan;165(1):119-25 [11125379.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1815-26 [11696442.001]
  • [Cites] Urology. 2001 Jun;57(6):1033-7 [11377299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3376-85 [12177097.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1174-8 [12800218.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1100-9 [12801870.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] J Pathol. 2004 Feb;202(2):233-40 [14743506.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1633-8 [15073850.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 May 1;196(3):422-30 [15094313.001]
  • [Cites] Urologe A. 2004 May;43(5):573-9 [15029477.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3935-6 [15217922.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):125-35 [15247353.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):549-53 [8621277.001]
  • [Cites] Anal Biochem. 1998 Sep 10;262(2):185-92 [9750131.001]
  • [Cites] Clin Chim Acta. 2004 Dec;350(1-2):181-8 [15530476.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):103-15 [15657340.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] J Urol. 2005 Dec;174(6):2191-6 [16280762.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] J Urol. 2007 Aug;178(2):459-63; discussion 463 [17561132.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1679-86 [17601725.001]
  • [Cites] J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1 [18289596.001]
  • [Cites] J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1 [18423693.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64 [18692327.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S11-5 [17084157.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • (PMID = 19229700.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091956-080012; United States / NCI NIH HHS / CA / P50 CA091956; United States / NCI NIH HHS / CA / CA091956; United States / NCI NIH HHS / CA / P50 CA091956-080012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS99244; NLM/ PMC2693083
  •  go-up   go-down


57. Huh JW, Park YA, Lee KY, Kim SA, Sohn SK: Recurrences after local excision for early rectal adenocarcinoma. Yonsei Med J; 2009 Oct 31;50(5):704-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The role of local excision in treating rectal cancer patients continues to be controversial.
  • The aim of this study was to evaluate the long-term oncological results of local excision for early rectal adenocarcinomas and review the outcomes of salvage therapy on rectal cancer patients.
  • The mean tumor distance from the anal verge was 5 cm (range, 1-10 cm).
  • Of the eight recurrent patients with surgical salvage, five survived with no evidence of disease at the time of this analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):875-9 [12130873.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):1075-90, x-xi [12507210.001]
  • [Cites] J Am Coll Surg. 2004 Sep;199(3):353-60 [15325603.001]
  • [Cites] Dis Colon Rectum. 1992 Feb;35(2):131-6 [1735314.001]
  • [Cites] Surgery. 1992 May;111(5):555-61 [1598675.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Jpn J Clin Oncol. 1998 Oct;28(10):621-5 [9839503.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):49-54 [10400036.001]
  • [Cites] Colorectal Dis. 2005 Jan;7(1):35-42 [15606582.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):223-34 [15615660.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1169-75 [15793645.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Dis Colon Rectum. 2007 Apr;50(4):523-33 [17285233.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jul-Aug;31(4):569-71 [17882033.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1520-5 [17674104.001]
  • [Cites] J Surg Res. 2008 Aug;148(2):244-50 [17936793.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):313-22 [10661337.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • (PMID = 19881976.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2768247
  • [Keywords] NOTNLM ; Recurrence / local excision / rectal adenocarcinoma
  •  go-up   go-down


58. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice.
  • RESULTS: Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease.
  • Twelve patients developed recurrent disease after radical salvage surgery.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Yu J, Zhang C, Wang YN, Hu YF, Cheng X, Li GX: [Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study].
  • OBJECTIVE: To evaluate the feasibility, safety, radicality and short-term outcome of laparoscopic total mesorectal excision(TME) in comparison with open procedure for the middle-lower rectal cancer.
  • METHODS: From November 2005 to October 2008, 93 patients with middle-lower rectal cancer received laparoscopic total mesorectal excision (LTME group), while 105 patients underwent conventional open TME (OTME group).
  • The anal sphincter preserved procedure accounted for 82.8% in LTME group and 81.9% in OTME group.
  • The recurrent rate and overall survival rate were 4.4% and 97.8% in LTME group, with no significant difference compared to those in OTME group (7.3% and 97.9%, P >0.05).
  • CONCLUSIONS: Laparoscopic TME for middle-low rectal cancer is safe and feasible, and can potentially offer all the benefits of a minimally invasive approach and achieve satisfactory oncological outcome,which may lead to a better future of the TME technique.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921566.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


60. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • Recurrent lesions were not seen during the first year after the first operation.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • 9 patients suffered from a recurrent tumour.
  • After a mean follow up of 44 months (r.: 18-84) 8 patients had deceased for recurrent disease, 15 were alive with a disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without disease.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


62. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the hypothesis that ABCs are lesions reactive to local hemodynamics has been challenged after the discovery of specific recurrent chromosomal abnormalities.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


63. Merg A, Wirtzfeld D, Wang J, Cheney R, Dunn KB, Rajput A: Viability of endoscopic and excisional treatment of early rectal carcinoids. J Gastrointest Surg; 2007 Jul;11(7):893-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rectal carcinoids were a mean 9.2 +/- 3.4 cm from the anal verge and a mean 9 +/- 6 mm in size.
  • No patient developed recurrent carcinoid disease for a 20-year overall survival of 70%.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Apr 1;79(7):1294-8 [9083149.001]
  • [Cites] Cancer. 1975 Mar;35(3):588-91 [1111928.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Int J Colorectal Dis. 1992 Feb;7(1):11-4 [1588217.001]
  • [Cites] Endoscopy. 1997 Mar;29(3):171-5 [9201465.001]
  • [Cites] Surg Today. 1997;27(2):112-9 [9017986.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1330-2 [15362745.001]
  • [Cites] Dis Colon Rectum. 1964 May-Jun;7:197-206 [14159370.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):67-71 [2294847.001]
  • [Cites] Jpn J Surg. 1990 Jul;20(4):468-71 [2201813.001]
  • [Cites] Am J Gastroenterol. 1993 Nov;88(11):1949-53 [8237948.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):91-7 [11786770.001]
  • [Cites] Am J Pathol. 1928 May;4(3):181-212.19 [19969788.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):717-25 [1643994.001]
  • [Cites] Dis Colon Rectum. 1996 Jun;39(6):643-8 [8646950.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Dis Colon Rectum. 1991 Jan;34(1):31-6 [1991417.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] Cancer. 1971 Jul;28(1):175-80 [5110628.001]
  • [Cites] Surg Gynecol Obstet. 1981 Mar;152(3):268-72 [7466571.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):549-56 [10998653.001]
  • [Cites] World J Surg. 1998 Jun;22(6):628-33; discussion 634 [9597939.001]
  • [Cites] Surgery. 1983 Oct;94(4):670-6 [6623366.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):262-5 [2393053.001]
  • (PMID = 17458590.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Tilney HS, Heriot AG, Trickett JP, Massouh H, Edwards DP, Mellor SG, Gudgeon AM: The use of intra-operative endo-anal ultrasound in perianal disease. Colorectal Dis; 2006 May;8(4):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of intra-operative endo-anal ultrasound in perianal disease.
  • Pathologies encountered were fistula-in-ano (42%), fissure-in-ano (26%), complicated perianal sepsis (16%) and carcinoma (5%).
  • In 22 cases (51.2%) the EAUS findings affected the surgical management (extent of muscle above a fistula 9 cases, extent of sphincterotomy 7 cases, site of sepsis identified 2 cases, exclusion of sepsis 2 cases, assessment of cancer resectability 1 case, biopsy of intersphincteric lesion 1 case).
  • While not essential, it is a useful adjunct especially in recurrent perianal sepsis, undiagnosed anorectal pain and anal fissure.
  • [MeSH-major] Anus Diseases / surgery. Anus Diseases / ultrasonography. Endosonography. Intraoperative Care. Rectal Fistula / surgery. Rectal Fistula / ultrasonography

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630240.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Sharma S, Sharma MC, Gupta DK, Sarkar C: Angiogenic patterns and their quantitation in high grade astrocytic tumors. J Neurooncol; 2006 Aug;79(1):19-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Limited follow up data showed all recurrent grade IV tumors to be of glomeruloid type.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1998 Apr;29(4):352-8 [9563784.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1216-21 [15026804.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Clin Neurosurg. 1976;23:440-53 [975695.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Acta Neuropathol. 1989;77(4):369-78 [2469286.001]
  • [Cites] Histopathology. 2001 Oct;39(4):402-8 [11683942.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):207-18 [7524960.001]
  • [Cites] Ai Zheng. 2005 Jan;24(1):19-22 [15642194.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):289-96 [12609567.001]
  • [Cites] Anal Cell Pathol. 1992 Nov;4(6):409-19 [1457384.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):75-85 [8699229.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):675-7 [15491962.001]
  • [Cites] J Pathol. 1992 Nov;168(3):257-62 [1281874.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):477-82 [10470824.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):134-41 [10393366.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):47-53 [11669558.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):46-52 [15850004.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):165-72 [11245275.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):530-4 [12101201.001]
  • [Cites] Leukemia. 2003 Jan;17(1):89-97 [12529665.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66 [11849564.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):516-26 [14595708.001]
  • [Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):681-95 [7980433.001]
  • [Cites] Histopathology. 2003 Apr;42(4):395-402 [12653952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207 [8380567.001]
  • [Cites] J Neurooncol. 1997 May;32(3):253-65 [9049887.001]
  • [Cites] Clin Exp Dermatol. 2003 May;28(3):310-4 [12780721.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):426-9 [15043465.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):902-9 [7525899.001]
  • [Cites] Adv Pharmacol. 1990;21:149-83 [2176094.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1369-76 [11516097.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):101-5 [10912927.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):133-43 [12744467.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2941-55 [15126324.001]
  • [Cites] Acta Neuropathol. 1993;85(5):508-14 [7684179.001]
  • (PMID = 16807783.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol; 2005 Sep 1;23(25):6199-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.
  • Also, hospital treatment was recorded for diseases possibly related to late side effects of rectal cancer treatment.
  • PATIENTS AND METHODS: Long-term morbidity was assessed in patients from the prospective randomized TME trial, which investigated the efficacy of 5 x 5 Gy before TME surgery for mobile rectal cancer.
  • Dutch patients without recurrent disease were sent a questionnaire.
  • However, irradiated patients, compared with nonirradiated patients, reported increased rates of fecal incontinence (62% v 38%, respectively; P < .001), pad wearing as a result of incontinence (56% v 33%, respectively; P < .001), anal blood loss (11% v 3%, respectively; P = .004), and mucus loss (27% v 15%, respectively; P = .005).
  • CONCLUSION: Although preoperative short-term radiotherapy for rectal cancer results in increased local control, there is more long-term bowel dysfunction in irradiated patients than in patients who undergo TME alone.
  • Rectal cancer patients should be informed on late morbidity of both radiotherapy and TME.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135487.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.
  • OBJECTIVE: To determine whether ImmunoCyt (uCyt+) immunofluorescence and cytokeratin 20 (CK20) immunocytochemistry add additional diagnostic value in the detection of urothelial carcinoma (UC) in samples of urine liquid-based cytology (LBC).
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


68. Gazdar AF, Gao B, Minna JD: Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer; 2010 Jun;68(3):309-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?
  • Perhaps the most important finding is that every important, recurrent genetic and epigenetic change including gene mutations, deletions, amplifications, translocations and methylation-induced gene silencing found in tumors has been identified in cell lines and vice versa.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Oncogene. 2009 Aug;28 Suppl 1:S24-31 [19680293.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):1018-20 [19692681.001]
  • [Cites] PLoS One. 2009;4(10):e7464 [19826477.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1537-47 [10793065.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):315-9 [12001993.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4577-86 [12085236.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):65-9 [12170765.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8510-4 [12466971.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2840-5 [15087401.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3060-71 [15126342.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):57-9 [15325095.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7047-52 [15258565.001]
  • [Cites] Cancer Res. 1980 Oct;40(10):3502-7 [6108156.001]
  • [Cites] Science. 1982 Jan 8;215(4529):181-2 [6274023.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Science. 1988 Jul 15;241(4863):353-7 [2838909.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Mar;25(3):527-34 [2539297.001]
  • [Cites] Eur Respir J. 1989 May;2(5):461-9 [2547647.001]
  • [Cites] Science. 1989 Oct 27;246(4929):491-4 [2554494.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):985-91 [8094998.001]
  • [Cites] Exp Cell Res. 1994 May;212(1):36-41 [8174640.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3375-8 [7936665.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5267-74 [17545606.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6007-11 [17616654.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):665-8 [17635116.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2652-63 [17913856.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60 [18006754.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):493-4 [18068625.001]
  • [Cites] Cell Biol Toxicol. 2007 Nov;23(6):367-72 [17522957.001]
  • [Cites] Mol Cancer. 2007;6:75 [18034892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Anal Biochem. 2008 Apr 15;375(2):237-48 [18211814.001]
  • [Cites] Hum Mutat. 2008 May;29(5):617-22 [18386774.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1053-9 [18304967.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:1-11 [8806089.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:24-31 [8806091.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:152-9 [8806097.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):308-19 [9559342.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):766-74 [9833771.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):2931-8 [9865903.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):991-1000 [10353731.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):725-31 [15677631.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1553-60 [15785753.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2446-8 [15944431.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):1-9 [16157194.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9601-8 [17018617.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e486 [17194187.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):85-102 [17311535.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):155-8 [16397413.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Differentiation. 2006 Apr;74(4):141-8 [16683984.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1927-35 [16705311.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]
  • [Cites] J Cell Mol Med. 2006 Jul-Sep;10(3):588-612 [16989723.001]
  • [Cites] Oncogene. 2008 Jul 31;27(33):4615-24 [18391978.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):810-8 [18523997.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4788-97 [18408757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14112-7 [18776048.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4226-7 [18987282.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3556-65 [19001438.001]
  • [Cites] Clin Transl Oncol. 2008 Nov;10(11):719-25 [19015068.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Jan;296(1):L82-91 [18978040.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):791-800 [19037103.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1795(2):92-103 [19167460.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):508-15 [19234440.001]
  • [Cites] Carcinogenesis. 2009 Apr;30(4):547-54 [19176640.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):489-500 [19477428.001]
  • [Cites] Cell. 2009 May 29;137(5):835-48 [19490893.001]
  • [Cites] Cancer Sci. 2009 Jun;100(6):1040-6 [19385971.001]
  • [Cites] PLoS One. 2009;4(7):e6146 [19582160.001]
  • (PMID = 20079948.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907-14; United States / NCI NIH HHS / CA / P50 CA070907-100003; United States / NCI NIH HHS / CA / CA070907-109001; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA084971; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-109001; United States / NCI NIH HHS / CA / CA070907-100003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 95
  • [Other-IDs] NLM/ NIHMS295304; NLM/ PMC3110769
  •  go-up   go-down


69. Hatoum OA, Binion DG, Phillips SA, O'Loughlin C, Komorowski RA, Gutterman DD, Otterson MF: Radiation induced small bowel "web" formation is associated with acquired microvascular dysfunction. Gut; 2005 Dec;54(12):1797-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These webs are likely to play a role in the pathogenesis of recurrent bowel obstruction.
  • METHODS: A 40 year old patient treated with radiation, two years previously, for an anal squamous cell cancer presented with recurrent small bowel obstruction.
  • [MeSH-minor] Adult. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Microcirculation / physiopathology. Microcirculation / radiation effects

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1986 Apr;10(2):155-70 [3705602.001]
  • [Cites] Cancer. 1975 Jun;35(6):1633-40 [1148997.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):516-26 [3384981.001]
  • [Cites] Pathol Annu. 1988;23 Pt 1:297-330 [3387138.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):865-9 [1914719.001]
  • [Cites] N Engl J Med. 1992 Sep 10;327(11):749-54 [1501650.001]
  • [Cites] Gastroenterology. 1993 Jun;104(6):1832-47 [8500743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Circ Res. 1998 Sep 7;83(5):501-7 [9734472.001]
  • [Cites] Free Radic Biol Med. 1998 Nov 1;25(7):826-31 [9823548.001]
  • [Cites] AMA Arch Intern Med. 1955 Jul;96(1):26-31 [14387317.001]
  • [Cites] Trends Cardiovasc Med. 2003 Jul;13(5):201-6 [12837583.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):58-69 [12851871.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9 [12714439.001]
  • [Cites] Surgery. 2004 Oct;136(4):854-60 [15467672.001]
  • [Cites] World J Surg. 1986 Apr;10(2):171-88 [3518250.001]
  • (PMID = 16127018.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774807
  •  go-up   go-down


70. Kuramoto L, Sobolev BG, Donaldson MG: On reporting results from randomized controlled trials with recurrent events. BMC Med Res Methodol; 2008;8:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On reporting results from randomized controlled trials with recurrent events.
  • Although a variety of statistical methods are available for the analysis of recurrent events, reporting the effect of an intervention on outcomes that recur is an area that remains poorly understood in clinical research.
  • The purpose of this paper is to outline guidelines for reporting results from RCTs where the outcome of interest is a recurrent event.
  • We reviewed the utility of regression models for the rate of a recurrent event by articulating the associated study questions, preenting the risk sets, and interpreting the regression coefficients.
  • RESULTS: Based on a single data set produced by simulation, we reported and contrasted results from statistical methods for evaluating treatment effect from an RCT with a recurrent outcome.
  • CONCLUSION: Our guidelines for reporting results from an RCT involving a recurrent event suggest that the study question and the objectives of the trial, such as assessing comparable groups and estimating effect size, should determine the statistical methods.
  • The guidelines should allow clinical researchers to report appropriate measures from an RCT for understanding the effect of intervention on the occurrence of a recurrent event.

  • MedlinePlus Health Information. consumer health - Falls.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1194-204 [17540006.001]
  • [Cites] BMJ. 1997 Oct 25;315(7115):1065-9 [9366737.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1191-4 [11323066.001]
  • [Cites] Stat Methods Med Res. 2002 Apr;11(2):141-66 [12040694.001]
  • [Cites] Eur Heart J. 2003 Jan;24(1):105-12 [12559942.001]
  • [Cites] N Engl J Med. 1988 Dec 29;319(26):1701-7 [3205267.001]
  • [Cites] Lancet. 1999 Jan 9;353(9147):93-7 [10023893.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):530-4 [15933397.001]
  • [Cites] Stat Med. 2006 Jan 15;25(1):165-79 [16217859.001]
  • [Cites] Lifetime Data Anal. 2006 Mar;12(1):69-95 [16583300.001]
  • [Cites] Spine J. 2006 Sep-Oct;6(5):488-93 [16934716.001]
  • [Cites] Stat Med. 2006 Oct 30;25(20):3518-33 [16345026.001]
  • [Cites] Lifetime Data Anal. 2006 Dec;12(4):389-406 [17031499.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):415-9 [17452736.001]
  • [Cites] Stat Methods Med Res. 2007 Apr;16(2):103-22 [17484295.001]
  • [Cites] Pulm Pharmacol Ther. 2008;21(1):88-97 [17350868.001]
  • [Cites] JAMA. 1989 May 12;261(18):2663-8 [2709546.001]
  • [Cites] J Gerontol. 1989 Jul;44(4):M112-7 [2738307.001]
  • [Cites] Am J Epidemiol. 1993 Feb 1;137(3):342-54 [8452142.001]
  • [Cites] BMJ. 1995 Feb 18;310(6977):454-6 [7873955.001]
  • [Cites] Stat Med. 1995 Oct 15;14(19):2081-98 [8552888.001]
  • [Cites] Stat Med. 1997 Sep 30;16(18):2029-47 [9308130.001]
  • [Cites] Stat Med. 2000 Jan 15;19(1):13-33 [10623910.001]
  • (PMID = 18513418.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2438437
  •  go-up   go-down


71. Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, De Paepe A, Eggert A, Laureys G, Vandesompele J, Speleman F: CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer; 2008;8:173
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recurrent loss of part of the long arm of chromosome 11 is a well established hallmark of a subtype of aggressive neuroblastomas.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 3.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Dec 1;62(2):139-46 [10610705.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):251-7 [9324132.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):44-9 [10913676.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):680-6 [11267980.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):427-30 [11279526.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):5-10 [11464905.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):24-7 [11464895.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):531-7 [11506492.001]
  • [Cites] Anal Biochem. 2002 Apr 1;303(1):95-8 [11906156.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):605-9 [12079507.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1525-31 [12202822.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5129-33 [12234973.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):377-86 [12450793.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):122-3 [12519963.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6320-6 [14559819.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):141-52 [9739017.001]
  • [Cites] Nat Med. 1999 Mar;5(3):286-91 [10086383.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4948-57 [10490829.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9280-8 [15516980.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):e9 [15653630.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2280-99 [15800319.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):337-50 [15837623.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):111-20 [15922863.001]
  • [Cites] BMC Bioinformatics. 2005;6:124 [15910681.001]
  • [Cites] BMC Genomics. 2005;6:97 [16000168.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5619-28 [16044164.001]
  • [Cites] Cancer Sci. 2005 Sep;96(9):543-52 [16128739.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2243-53 [16306521.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7902-12 [16103881.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D684-8 [16381959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7471-5 [16648254.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6050-62 [16778177.001]
  • [Cites] BMC Bioinformatics. 2006;7:431 [17022803.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Dec;45(12):1130-42 [16958102.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5070-8 [17075126.001]
  • [Cites] BMC Bioinformatics. 2006;7:496 [17094804.001]
  • [Cites] Genome Biol. 2006;7(9):R84 [16989664.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40330-40 [17068332.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108 [17823929.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):769-71 [14662434.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):294-305 [14970278.001]
  • [Cites] Am J Hum Genet. 2004 Apr;74(4):761-4 [15024693.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1599-609 [15090470.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):727-30 [15338462.001]
  • [Cites] Cell Growth Differ. 1991 May;2(5):245-55 [1679663.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] Am J Med Genet. 1995 Jul 31;58(1):46-9 [7573155.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2483-7 [10811128.001]
  • (PMID = 18559103.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2442116
  •  go-up   go-down


72. Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, Minsky BD, Cohen AM, Paty PB: Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum; 2005 Jun;48(6):1169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical salvage of recurrent rectal cancer after transanal excision.
  • PURPOSE: This study examines surgical salvage of locally recurrent rectal cancer following transanal excision of early tumors.
  • METHODS: Through retrospective review of a colorectal database we identified 50 patients who underwent attempted surgical salvage for local recurrence following initial transanal excision of T1 or T2 rectal cancer.
  • CONCLUSION: Pelvic recurrence following transanal excision of early rectal cancer is often locally advanced, requiring an extended pelvic dissection with en bloc resection of adjacent pelvic organs to achieve salvage.
  • When contemplating local excision for early rectal cancer, the risk of local recurrence, the extent and morbidity of surgery required for salvage, and the modest cure rate following salvage should be considered.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Colectomy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793645.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Bell SW, Dehni N, Chaouat M, Lifante JC, Parc R, Tiret E: Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection. Br J Surg; 2005 Apr;92(4):482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Significant morbidity can result from perineal wounds, particularly after radiotherapy and extensive resection for cancer.
  • Twenty-six patients had surgery for recurrent or persistent epidermoid anal cancer or low rectal cancer, and 21 had high-dose preoperative radiotherapy.
  • [MeSH-minor] Adult. Aged. Anus Neoplasms / radiotherapy. Anus Neoplasms / surgery. Female. Humans. Length of Stay. Middle Aged. Neoplasm Recurrence, Local / surgery. Prospective Studies. Radiation Injuries / etiology. Radiotherapy / adverse effects. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Reoperation. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • (PMID = 15736219.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Leblanc J, Kongkam P: Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report. Clin Med Oncol; 2009;3:59-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report.
  • A 69-year-old woman with a history of uT2 N0 post-treated anal squamous cell cancer (SCC) presented for EUS for perianal pain.
  • A sigmoidoscopy revealed mild narrowing of the anal canal and an ulcerated friable mucosa in the same area.
  • While endoscopic biopsy of suspected anal recurrences is usually sufficient, histologic or cytologic confirmation are necessary, as radiation-induced changes are difficult to differentiate from tumor recurrence.
  • This case demonstrates that EUS-FNA is useful in surveillance of anal SCC when there is a high clinical suspicion of recurrence.